Skip to main content
Psychedex
Sources
25
17 moderate · 8 weak

Studies and references cited across this article, graded by evidence strength.

Claims checked
91
57verified34inconclusive

Inconclusive means the cited source neither confirms nor refutes the claim — a lower-confidence badge, not an error.

Generated
Apr 25, 2026 · pipeline-v5
Values approved
82/82 (100%)

Data points an editor reviewed and accepted for publication.

01

Value Provenance

Dosing

oraltrace

FieldPublishedAI ProposedConfidence
Threshold25 mg25 mglow
Low40–80 mg40–80 mglow
Common100–120 mg100–120 mglow
Strong120–150 mg120–150 mglow
Heavy150+ mg150+ mglow
Editorial

Common dose (100-120 mg) confirmed by Shulgin's PiHKAL account at 110 mg. Threshold, light, strong, and heavy ranges inferred by structural analogy with MDMA dose ratios and the documented absence of psychoactivity at 100-110 mg. No published dose-response data exist for PMMA in humans. Fatal outcomes documented from single-tablet ingestions in the presumed 100-200 mg range.

Reasoning

Common dose (100-120 mg) confirmed by Shulgin's PiHKAL account at 110 mg. Threshold, light, strong, and heavy ranges inferred by structural analogy with MDMA dose ratios and the documented absence of psychoactivity at 100-110 mg. No published dose-response data exist for PMMA in humans. Fatal outcomes documented from single-tablet ingestions in the presumed 100-200 mg range.

Evidence basis: community_consensus_large

Duration

oral

FieldPublishedAI ProposedConfidence
Onsettrace45–90 minutes45–90 minuteslow
Editorial

Rat plasma Tmax ~30 min, brain Tmax ~60 min at higher doses (Páleníček 2011). Human onset inferred to be slower than MDMA (30-45 min). No controlled human onset data.

Reasoning

Rat plasma Tmax ~30 min, brain Tmax ~60 min at higher doses (Páleníček 2011). Human onset inferred to be slower than MDMA (30-45 min). No controlled human onset data.

Evidence basis: animal_study

Come uptrace30–45 minutes30–45 minuteslow
Editorial

Inferred from rat brain penetration kinetics (Páleníček 2011) and MDMA analogy. No human data.

Reasoning

Inferred from rat brain penetration kinetics (Páleníček 2011) and MDMA analogy. No human data.

Evidence basis: structural_analogy

Peaktrace60–90 minutes60–90 minuteslow
Editorial

Inferred from Shulgin's report of effects peaking then resolving by ~4 hours at 110 mg, combined with rat brain Cmax timing.

Reasoning

Inferred from Shulgin's report of effects peaking then resolving by ~4 hours at 110 mg, combined with rat brain Cmax timing.

Evidence basis: community_consensus_small

Offsettrace45–60 minutes45–60 minuteslow
Editorial

Shulgin returned to baseline by ~hour 4. Offset estimated as the decline phase between peak and resolution.

Reasoning

Shulgin returned to baseline by ~hour 4. Offset estimated as the decline phase between peak and resolution.

Evidence basis: community_consensus_small

Totaltrace3–5 hours3–5 hoursmedium
Editorial

Shulgin returned to baseline by approximately hour 4 at 110 mg (PiHKAL). Rat half-life ~1.0 hour supports a 3-5 hour total window. No controlled human study.

Reasoning

Shulgin returned to baseline by approximately hour 4 at 110 mg (PiHKAL). Rat half-life ~1.0 hour supports a 3-5 hour total window. No controlled human study.

Evidence basis: community_consensus_small

After effectstrace2–4 hours2–4 hourslow
Editorial

No published aftereffect data. Estimated by analogy with MDMA (2-6 hours aftereffects). PMMA's shorter subjective duration suggests a shorter aftereffect window.

Reasoning

No published aftereffect data. Estimated by analogy with MDMA (2-6 hours aftereffects). PMMA's shorter subjective duration suggests a shorter aftereffect window.

Evidence basis: structural_analogy

Safety

Toxicity Profiletrace

FieldPublishedAI ProposedConfidence
Acutecriticalcriticalhigh
Chronicmoderatemoderatehigh
Organs Affectedcardiovascular, brain, kidney, respiratorycardiovascular, brain, kidney, respiratoryhigh
Editorial

Acute critical: documented fatalities from single-tablet ingestions, narrow margin between active and lethal doses, mouse LD50 53-63 mg/kg (Glennon 1988), median fatal human blood concentration 1.92 mg/L vs non-fatal 0.07 mg/L (Vevelstad 2012). Chronic moderate: PKCδ-mediated dopaminergic neurotoxicity demonstrated in mice (Shin 2016) but no human chronic exposure data; downgraded from high because evidence is animal-only.

Reasoning

Acute critical: documented fatalities from single-tablet ingestions, narrow margin between active and lethal doses, mouse LD50 53-63 mg/kg (Glennon 1988), median fatal human blood concentration 1.92 mg/L vs non-fatal 0.07 mg/L (Vevelstad 2012). Chronic moderate: PKCδ-mediated dopaminergic neurotoxicity demonstrated in mice (Shin 2016) but no human chronic exposure data; downgraded from high because evidence is animal-only.

Evidence basis: published_case_series

Dependence Profiletrace

FieldPublishedAI ProposedConfidence
Physicalnonenonelow
Psychologicalnegligiblenegligiblelow
Compulsive Redosinglowlowlow
Dose Escalationnegligiblenegligiblelow
Editorial

No PMMA-specific dependence, self-administration, or conditioned place preference data exist. Assessment entirely class-inferred from MDMA (low dependence liability) and the compound's serotonin-preferring pharmacological profile. Gołembiowska 2015 noted dopaminergic changes suggesting dependence potential but this is speculative inference from acute neurochemistry.

Reasoning

No PMMA-specific dependence, self-administration, or conditioned place preference data exist. Assessment entirely class-inferred from MDMA (low dependence liability) and the compound's serotonin-preferring pharmacological profile. Gołembiowska 2015 noted dopaminergic changes suggesting dependence potential but this is speculative inference from acute neurochemistry.

Evidence basis: structural_analogy

Withdrawal Profiletrace

FieldPublishedAI ProposedConfidence
Severitynonenonelow
Symptoms——low
FatalNoNolow
Medical SupervisionNot requiredNot requiredlow
Editorial

No withdrawal syndrome has been documented or inferred for PMMA. Class analogy with MDMA suggests no physical withdrawal.

Reasoning

No withdrawal syndrome has been documented or inferred for PMMA. Class analogy with MDMA suggests no physical withdrawal.

Evidence basis: structural_analogy

Tolerance Profiletrace

FieldPublishedAI ProposedConfidence
Buildupmoderatemoderatelow
Half-life——low
Full Reset——low
Cross-tolerancesMDMA, PMA, amphetamineMDMA, PMA, amphetaminelow
Editorial

Entirely structural analogy with MDMA. No PMMA-specific tolerance studies exist. Cross-tolerance with MDMA, PMA, and amphetamine inferred from shared monoamine transporter mechanisms. Buildup rated moderate by MDMA analogy (not as rapid as serotonergic psychedelic tachyphylaxis, not as slow as opioid tolerance).

Reasoning

Entirely structural analogy with MDMA. No PMMA-specific tolerance studies exist. Cross-tolerance with MDMA, PMA, and amphetamine inferred from shared monoamine transporter mechanisms. Buildup rated moderate by MDMA analogy (not as rapid as serotonergic psychedelic tachyphylaxis, not as slow as opioid tolerance).

Evidence basis: structural_analogy

Effects & Profile

Contraindications

FieldPublishedAI ProposedConfidence
psychiatric MAOI therapytraceabsoluteabsolutehigh
Editorial

PMMA inhibits MAO-A (IC50 ~1700 nM; Reyes-Parada 2019). Dual MAO inhibition with a serotonin releaser is a well-established lethal combination.

Reasoning

PMMA inhibits MAO-A (IC50 ~1700 nM; Reyes-Parada 2019). Dual MAO inhibition with a serotonin releaser is a well-established lethal combination.

psychiatric SSRI/SNRI therapytraceabsoluteabsolutehigh
Editorial

Class-inferred from PMMA's dual serotonergic mechanism (release + MAO-A inhibition) combined with known SSRI serotonin syndrome risks. Multiple fatal PMMA cases involved polydrug serotonergic exposure.

Reasoning

Class-inferred from PMMA's dual serotonergic mechanism (release + MAO-A inhibition) combined with known SSRI serotonin syndrome risks. Multiple fatal PMMA cases involved polydrug serotonergic exposure.

metabolic CYP2D6 poor metabolizer statustraceabsoluteabsolutehigh
Editorial

Vevelstad 2017 established CYP2D6 as the primary PMMA metabolic enzyme. Ultrarapid metabolizers form significantly more metabolites than poor metabolizers. Fatal blood concentrations overlap with expected poor-metabolizer pharmacokinetics at common doses.

Reasoning

Vevelstad 2017 established CYP2D6 as the primary PMMA metabolic enzyme. Ultrarapid metabolizers form significantly more metabolites than poor metabolizers. Fatal blood concentrations overlap with expected poor-metabolizer pharmacokinetics at common doses.

cardiovascular pre-existing cardiovascular diseasetracerelativerelativehigh
Editorial

Shulgin documented tachycardia (pulse >100 bpm) at 110 mg. Cardiovascular collapse is a documented mode of PMMA-related death (Vevelstad 2012, Nicol 2015). ADF Australia lists cardiac conditions as a risk factor.

Reasoning

Shulgin documented tachycardia (pulse >100 bpm) at 110 mg. Cardiovascular collapse is a documented mode of PMMA-related death (Vevelstad 2012, Nicol 2015). ADF Australia lists cardiac conditions as a risk factor.

cardiovascular hypertensiontracerelativerelativemedium
Editorial

ADF Australia and DrugFacts UK list hypertension as a risk factor for PMA/PMMA. Blood pressure elevation documented in Shulgin's account.

Reasoning

ADF Australia and DrugFacts UK list hypertension as a risk factor for PMA/PMMA. Blood pressure elevation documented in Shulgin's account.

metabolic hyperthyroidismtracerelativerelativemedium
Editorial

ADF Australia and DrugFacts UK list hyperthyroidism as a risk factor for PMA/PMMA use.

Reasoning

ADF Australia and DrugFacts UK list hyperthyroidism as a risk factor for PMA/PMMA use.

hepatic hepatic impairmenttracerelativerelativemedium
Editorial

Inferred from PMMA's CYP2D6-dependent metabolism (Vevelstad 2017) and general hepatic pharmacology. No PMMA-specific hepatic impairment data.

Reasoning

Inferred from PMMA's CYP2D6-dependent metabolism (Vevelstad 2017) and general hepatic pharmacology. No PMMA-specific hepatic impairment data.

renal renal impairmenttracerelativerelativemedium
Editorial

Jensen 2020 established OCT2 as a PMMA excretion transporter. Renal failure documented in PMMA-surviving patients (Vevelstad 2012).

Reasoning

Jensen 2020 established OCT2 as a PMMA excretion transporter. Renal failure documented in PMMA-surviving patients (Vevelstad 2012).

pregnancy breastfeeding pregnancytraceabsoluteabsolutemedium
Editorial

Class-level contraindication for sympathomimetic amphetamine derivatives in pregnancy. No PMMA-specific reproductive data.

Reasoning

Class-level contraindication for sympathomimetic amphetamine derivatives in pregnancy. No PMMA-specific reproductive data.

Timeline Phases

oral

FieldPublishedAI ProposedConfidence
Onsettrace2700–5400 sec(i=0.05)2700–5400 sec(i=0.05)low
Editorial

Timeline derived primarily from Shulgin's single-subject account at 110 mg (return to baseline ~4 hours) and rat PK data (serum Tmax ~30 min, brain Tmax ~60 min at higher doses). No controlled human duration study exists. Rat half-life ~1.0 hour supports a 3\u20135 hour total experience window. Phase boundaries are estimated — no published human phase-by-phase data available.

Reasoning

Timeline derived primarily from Shulgin's single-subject account at 110 mg (return to baseline ~4 hours) and rat PK data (serum Tmax ~30 min, brain Tmax ~60 min at higher doses). No controlled human duration study exists. Rat half-life ~1.0 hour supports a 3\u20135 hour total experience window. Phase boundaries are estimated — no published human phase-by-phase data available.

Come uptrace1800–2700 sec(i=0.30)1800–2700 sec(i=0.30)low
Editorial

Timeline derived primarily from Shulgin's single-subject account at 110 mg (return to baseline ~4 hours) and rat PK data (serum Tmax ~30 min, brain Tmax ~60 min at higher doses). No controlled human duration study exists. Rat half-life ~1.0 hour supports a 3\u20135 hour total experience window. Phase boundaries are estimated — no published human phase-by-phase data available.

Reasoning

Timeline derived primarily from Shulgin's single-subject account at 110 mg (return to baseline ~4 hours) and rat PK data (serum Tmax ~30 min, brain Tmax ~60 min at higher doses). No controlled human duration study exists. Rat half-life ~1.0 hour supports a 3\u20135 hour total experience window. Phase boundaries are estimated — no published human phase-by-phase data available.

Peaktrace3600–5400 sec(i=1.00)3600–5400 sec(i=1.00)low
Editorial

Timeline derived primarily from Shulgin's single-subject account at 110 mg (return to baseline ~4 hours) and rat PK data (serum Tmax ~30 min, brain Tmax ~60 min at higher doses). No controlled human duration study exists. Rat half-life ~1.0 hour supports a 3\u20135 hour total experience window. Phase boundaries are estimated — no published human phase-by-phase data available.

Reasoning

Timeline derived primarily from Shulgin's single-subject account at 110 mg (return to baseline ~4 hours) and rat PK data (serum Tmax ~30 min, brain Tmax ~60 min at higher doses). No controlled human duration study exists. Rat half-life ~1.0 hour supports a 3\u20135 hour total experience window. Phase boundaries are estimated — no published human phase-by-phase data available.

Resolutiontrace2700–3600 sec(i=0.20)2700–3600 sec(i=0.20)low
Editorial

Timeline derived primarily from Shulgin's single-subject account at 110 mg (return to baseline ~4 hours) and rat PK data (serum Tmax ~30 min, brain Tmax ~60 min at higher doses). No controlled human duration study exists. Rat half-life ~1.0 hour supports a 3\u20135 hour total experience window. Phase boundaries are estimated — no published human phase-by-phase data available.

Reasoning

Timeline derived primarily from Shulgin's single-subject account at 110 mg (return to baseline ~4 hours) and rat PK data (serum Tmax ~30 min, brain Tmax ~60 min at higher doses). No controlled human duration study exists. Rat half-life ~1.0 hour supports a 3\u20135 hour total experience window. Phase boundaries are estimated — no published human phase-by-phase data available.

Afterglowtrace7200–14400 sec(i=0.05)7200–14400 sec(i=0.05)low
Editorial

Timeline derived primarily from Shulgin's single-subject account at 110 mg (return to baseline ~4 hours) and rat PK data (serum Tmax ~30 min, brain Tmax ~60 min at higher doses). No controlled human duration study exists. Rat half-life ~1.0 hour supports a 3\u20135 hour total experience window. Phase boundaries are estimated — no published human phase-by-phase data available.

Reasoning

Timeline derived primarily from Shulgin's single-subject account at 110 mg (return to baseline ~4 hours) and rat PK data (serum Tmax ~30 min, brain Tmax ~60 min at higher doses). No controlled human duration study exists. Rat half-life ~1.0 hour supports a 3\u20135 hour total experience window. Phase boundaries are estimated — no published human phase-by-phase data available.

Dose Tier Summaries

thresholdtrace
low

At threshold doses (approximately 25–40 mg oral), effects are sub-perceptual or barely perceptible. A mild increase in heart rate may be noticed, along with subtle restlessness or body awareness. No psychoactive, empathogenic, or visual effects are expected at this level. Physically, slight sympathomimetic activation — mild tachycardia and peripheral warmth — may occur. These effects are easily overlooked and indistinguishable from caffeine or mild anxiety.

Editorial

No human data exist for PMMA at threshold doses. Shulgin reported no psychoactivity at 100–110 mg. Threshold inferred as approximately 25–40% of common dose range by analogy with MDMA threshold-to-common ratio, but this is speculative. No published threshold data for PMMA.

Reasoning

No human data exist for PMMA at threshold doses. Shulgin reported no psychoactivity at 100–110 mg. Threshold inferred as approximately 25–40% of common dose range by analogy with MDMA threshold-to-common ratio, but this is speculative. No published threshold data for PMMA.

Evidence basis: structural_analogy

lighttrace
low

At light doses (approximately 40–80 mg oral), sympathomimetic effects become more apparent: increased heart rate, mild blood pressure elevation, and possible appetite suppression. Some users of tablets sold as ecstasy at this range may report mild stimulation or wakefulness without distinct empathogenic or psychedelic character. Physical effects include tachycardia, mild vasoconstriction, and possible onset of sweating. The absence of prominent subjective psychoactivity at this range — consistent with Shulgin's observations — may lead users to believe the tablet is inactive and redose, which is the primary danger at this tier.

Editorial

Shulgin reported cardiovascular effects without psychoactivity at 100–110 mg. Light dose range inferred by structural analogy with MDMA (40–75 mg light). No published human data at these specific doses for PMMA.

Reasoning

Shulgin reported cardiovascular effects without psychoactivity at 100–110 mg. Light dose range inferred by structural analogy with MDMA (40–75 mg light). No published human data at these specific doses for PMMA.

Evidence basis: structural_analogy

commontrace
medium

At common doses (100–120 mg oral), the full PMMA experience — such as it is — manifests primarily as physiological activation rather than psychoactivity. Tachycardia (pulse exceeding 100 bpm), compulsive yawning, and eye muscle disturbance resembling nystagmus were documented at 110 mg by Shulgin. No euphoria, empathy enhancement, or perceptual effects were reported. Physical effects dominate: elevated heart rate and blood pressure, excessive sweating, possible bruxism, and pupil dilation. The onset is notably slow (estimated 45–90 minutes), and the disconnect between peripheral effects and absent central psychoactivity is characteristic. Total duration is approximately 3–5 hours. The slow onset at this range is the most dangerous feature — users expecting MDMA-like effects within 30 minutes may redose before PMMA's full action develops, pushing total intake into the lethal range.

Editorial

Common dose range (100–120 mg) aligns with Shulgin's documented human trial at 110 mg in PiHKAL. Effects described are directly from Shulgin's report. Duration estimate from Shulgin's return to baseline by hour 4.

Reasoning

Common dose range (100–120 mg) aligns with Shulgin's documented human trial at 110 mg in PiHKAL. Effects described are directly from Shulgin's report. Duration estimate from Shulgin's return to baseline by hour 4.

Evidence basis: community_consensus_large

strongtrace
low

At strong doses (120–150 mg oral), the risk of serotonin syndrome and life-threatening hyperthermia increases substantially. No controlled human data exist at this range. Based on PMMA's dual serotonergic mechanism (release plus MAO-A inhibition), serotonin-mediated toxicity — agitation, muscle rigidity, autonomic instability, and dangerous hyperthermia — becomes increasingly likely. Physically, severe tachycardia, profuse sweating, hyperthermia (particularly in warm or crowded environments), and possible convulsions may occur. The boundary between strong and lethal doses is not well-defined; fatal outcomes have occurred across a wide concentration range. This dose range approaches documented lethal territory. CYP2D6 poor metabolizers may reach toxic blood concentrations at the lower end of this range.

Editorial

No human experiential data exist above 110 mg. Strong dose range inferred from the gap between Shulgin's common dose (110 mg) and documented fatal outcomes. Fatal blood concentrations begin at 0.6 mg/L peripheral blood (Vevelstad 2012). Dose-concentration relationship in humans unknown.

Reasoning

No human experiential data exist above 110 mg. Strong dose range inferred from the gap between Shulgin's common dose (110 mg) and documented fatal outcomes. Fatal blood concentrations begin at 0.6 mg/L peripheral blood (Vevelstad 2012). Dose-concentration relationship in humans unknown.

Evidence basis: structural_analogy

heavytrace
low

Doses exceeding 150 mg oral enter a range with high probability of life-threatening toxicity. At these doses, the combined serotonin release and MAO-A inhibition produce serotonin syndrome: severe hyperthermia, muscle rigidity, seizures, cardiovascular collapse, and multiorgan failure. Multiple documented fatalities have occurred from single-tablet exposures. Physical deterioration follows a characteristic trajectory: agitation and autonomic instability progress to extreme hyperthermia (body temperatures exceeding 40°C), convulsions, cardiac arrest, and acute respiratory distress. Renal failure has been documented in survivors. There is no established safe ceiling for PMMA. The margin between common and lethal doses is among the narrowest of any recreational substance. Emergency medical intervention is critical at any sign of serotonin syndrome.

Editorial

Heavy dose range based on documented fatal cases: Norwegian epidemic median fatal concentration 1.92 mg/L (Vevelstad 2012), Canadian series with 21 deaths (Nicol 2015). No dose-concentration curve established in humans. Fatal outcomes documented from single-tablet ingestions suggesting doses in the 100–200 mg range can be lethal.

Reasoning

Heavy dose range based on documented fatal cases: Norwegian epidemic median fatal concentration 1.92 mg/L (Vevelstad 2012), Canadian series with 21 deaths (Nicol 2015). No dose-concentration curve established in humans. Fatal outcomes documented from single-tablet ingestions suggesting doses in the 100–200 mg range can be lethal.

Evidence basis: published_case_series

02

History

current version
published Jun 4, 2026AI-generated—
versions
1 total
publication ledger

backfill Jun 4, 2026

Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.

full version history suggest a correctioncontact@psychedex.org
03

Sources

17 moderate · 8 weak
  1. [1]
    moderate
    Monoamine transporter and receptor interaction profiles of a new series of designer cathinones
    Simmler LD, Rickli A, Hoener MC, Liechti ME · 2014 · Neuropharmacology
    doi.org/10.1016/j.neuropharm.2013.11.008pubmed 242750465 claims checked3 verified2 inconclusive
  2. [2]
    moderate
    Amphetamine Derivatives as Monoamine Oxidase Inhibitors
    Reyes-Parada M, Iturriaga-Vasquez P, Cassels BK · 2019 · Frontiers in Pharmacology
    doi.org/10.3389/fphar.2019.01590pubmed 320382577 claims checked3 verified4 inconclusive
  3. [3]
    moderate
    A preliminary behavioral investigation of PMMA, the 4-methoxy analog of methamphetamine
    Glennon RA, Ismaiel AE, Martin B, Poff D, Sutton M · 1988 · Pharmacology, Biochemistry, and Behavior
    pubmed 32522645 claims checked4 verified1 inconclusive
  4. [4]
    weak
    The PMMA epidemic in Norway: comparison of fatal and non-fatal intoxications
    Vevelstad M, Øiestad EL, Middelkoop G, Hasvold I, Lilleng P, Delaveris GJ, Eggen T, Mørland J, Arnestad M · 2012 · Forensic Science International
    doi.org/10.1016/j.forsciint.2011.12.014pubmed 2225796813 claims checked7 verified6 inconclusive
  5. [5]
    weak
    Deaths from exposure to paramethoxymethamphetamine in Alberta and British Columbia, Canada: a case series
    Nicol JJ, Yarema MC, Jones GR, Martz W, Purssell RA, MacDonald JC, Wishart I, Durigon M, Tzemis D, Buxton JA · 2015 · CMAJ Open
    doi.org/10.9778/cmajo.20140070pubmed 258443758 claims checked5 verified3 inconclusive
  6. [6]
    moderate
    Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling
    Liechti ME · 2015 · Swiss Medical Weekly
    doi.org/10.4414/smw.2015.14043pubmed 255880186 claims checked2 verified4 inconclusive
  7. [7]
    moderate
    Behavioral, hyperthermic and pharmacokinetic profile of para-methoxymethamphetamine (PMMA) in rats
    Páleníček T, Balíková M, Rohanová M, Novák T, Horáček J, Fujáková M, Höschl C · 2011 · Pharmacology, Biochemistry, and Behavior
    doi.org/10.1016/j.pbb.2010.12.011pubmed 211671956 claims checked3 verified3 inconclusive
  8. [8]
    moderate
    Studies on Para-Methoxymethamphetamine (PMMA) Metabolite Pattern and Influence of CYP2D6 Genetics in Human Liver Microsomes and Authentic Samples from Fatal PMMA Intoxications
    Vevelstad M, Øiestad EL, Nerem E, Arnestad M, Bogen IL · 2017 · Drug Metabolism and Disposition
    doi.org/10.1124/dmd.117.077263pubmed 2897866113 claims checked9 verified4 inconclusive
  9. [9]
    weak
    Council decides PMMA should be placed under control
    EMCDDA/EUDA · 2002
    linkno claims checked
  10. [10]
    weak
    A fatal paramethoxymethamphetamine intoxication
    Becker J, Neis P, Röhrich J, Zörntlein S · 2003 · Legal Medicine (Tokyo)
    pubmed 129355734 claims checked4 verified
  11. [11]
    weak
    Para-Methoxy-N-methylamphetamine (PMMA) - HandWiki
    HandWiki contributors · 2023
    linkno claims checked
  12. [12]
    moderate
    Synthesis and organic impurity profiling of 4-methoxymethamphetamine hydrochloride and its precursors
    Tam R, Heather E, Shimmon R, Lam B, McDonagh AM · 2017 · Forensic Science International
    doi.org/10.1016/j.forsciint.2016.11.041pubmed 280655562 claims checked1 verified1 inconclusive
  13. [13]
    moderate
    Stimulus properties of PMMA: effect of optical isomers and conformational restriction
    Young R, Dukat M, Malmusi L, Glennon RA · 1999 · Pharmacology, Biochemistry, and Behavior
    pubmed 105153291 claim checked1 verified
  14. [14]
    moderate
    Effect of Some Psychoactive Drugs Used as 'Legal Highs' on Brain Neurotransmitters
    Gołembiowska K, Jurczak A, Kamińska K, Noworyta K, Górska A · 2015 · Neurotoxicity Research
    doi.org/10.1007/s12640-015-9569-1pubmed 265013525 claims checked2 verified3 inconclusive
  15. [15]
    moderate
    Studies on distribution and metabolism of para-methoxymethamphetamine (PMMA) in rats after subcutaneous administration
    Rohanova M, Balikova M · 2009 · Toxicology
    doi.org/10.1016/j.tox.2009.02.003pubmed 194289441 claim checked1 inconclusive
  16. [16]
    moderate
    Liquid chromatography-quadrupole time-of-flight mass spectrometry for screening in vitro drug metabolites in humans: investigation on seven phenethylamine-based designer drugs
    Lai FY, Erratico C, Kinyua J, Mueller JF, Covaci A, van Nuijs AL · 2015 · Journal of Pharmaceutical and Biomedical Analysis
    doi.org/10.1016/j.jpba.2015.06.016pubmed 261129253 claims checked2 verified1 inconclusive
  17. [17]
    moderate
    New designer drug p-methoxymethamphetamine: studies on its metabolism and toxicological detection in urine using gas chromatography-mass spectrometry
    Staack RF, Fehn J, Maurer HH · 2003 · Journal of Chromatography B
    pubmed 127268412 claims checked2 verified
  18. [18]
    moderate
    Cellular Uptake of Psychostimulants - Are High- and Low-Affinity Organic Cation Transporters Drug Traffickers?
    Jensen O, Rafehi M, Gebauer L, Brockmöller J · 2020 · Frontiers in Pharmacology
    doi.org/10.3389/fphar.2020.609811pubmed 335518123 claims checked2 verified1 inconclusive
  19. [19]
    moderate
    PKCδ knockout mice are protected from para-methoxymethamphetamine-induced mitochondrial stress and associated neurotoxicity in the striatum of mice
    Shin EJ, Dang DK, Tran HQ, Nam Y, Jeong JH, Lee YH, Park KT, Lee YS, Jang CG, Hong JS, Nabeshima T, Kim HC · 2016 · Neurochemistry International
    doi.org/10.1016/j.neuint.2016.09.008pubmed 276230934 claims checked4 verified
  20. [20]
    moderate
    MDMA (3,4-Methylenedioxymethamphetamine) Analogues as Tools to Characterize MDMA-Like Effects: An Approach to Understand Entactogen Pharmacology
    Sáez-Briones P, Hernández A · 2013 · Current Neuropharmacology
    doi.org/10.2174/1570159x11311050007pubmed 244038761 claim checked1 verified
  21. [21]
    moderate
    PMMA-stimulus generalization to the optical isomers of MBDB and 3,4-DMA
    Rangisetty JB, Bondarev ML, Chang-Fong J, Young R, Glennon RA · 2001 · Pharmacology, Biochemistry, and Behavior
    pubmed 114200941 claim checked1 verified
  22. [22]
    weak
    PMA and PMMA - Alcohol and Drug Foundation Australia
    Alcohol and Drug Foundation · 2023
    linkno claims checked
  23. [23]
    weak
    PMMA/PMA - DrugFacts UK
    DrugFacts UK · 2022
    linkno claims checked
  24. [24]
    moderate
    N-Methyl-1-(4-methoxyphenyl)-2-aminopropane (PMMA) and N-Methyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDMA) produce non-identical discriminative stimuli in rats
    Glennon RA, Young R, Dukat M, Chang-Fong J, El-Zahabi M · 2007 · Pharmacology, Biochemistry, and Behavior
    pubmed 173072471 claim checked1 verified
  25. [25]
    weak
    Schedules of Controlled Substances: Placement of PMMA in Schedule I
    DEA, US Department of Justice · 2021
    linkno claims checked
04

Claim Verification

Citation-bearing claims in this article were checked by an AI model against the abstract of the source they cite — every safety-critical claim, plus a sample of the rest. Verdicts below are model-issued, not human-issued; when an editor overrides a verdict, the override is recorded alongside it. Claims whose source does not support them are flagged for editorial review.

summary10 claims5verified5inconclusive
inconclusivePMMA was first characterised in animals by Glennon and colleagues in 1988 and documented in Shulgin's PiHKAL (1991) under entry #130 as "METHYL-MA." No clinical therapeutic application has ever been proposed, and no clinical trials have been registered[3]model confidence 75%
Inconclusive

Abstract confirms animal characterization of stimulus properties, locomotor effects, and LD50, supporting the Glennon characterization aspect. However, the specific '1988' date, PiHKAL entry #130, 'METHYL-MA' name, and absence of clinical trials are not verifiable from the abstract.

Racemic PMMA produced neither DOM-like nor amphetamine-like stimulus effects. LD50 isolated 63 mg/kg, aggregated 53 mg/kg in mice.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedPMMA's research significance is almost entirely forensic and toxicological: a series of mass-casualty events — 12 deaths in Norway (2010–2011), 21 in Canada (2011), and additional fatalities across Europe and South America — established PMMA as one of the most dangerous adulterants in the illicit MDMA supply.[4]model confidence 90%
Verified

Abstract directly confirms 12 Norwegian fatalities (Jul 2010–Jan 2011) and establishes PMMA's forensic toxicological significance. The claim's Norwegian figures are verified; the Canada/Europe/South America components would be covered by other citations.

12 fatal and 22 non-fatal PMMA cases in Norway (Jul 2010-Jan 2011).

checked by claude-sonnet-4-6 · Apr 25, 2026

inconclusivePMMA's research significance is almost entirely forensic and toxicological: a series of mass-casualty events — 12 deaths in Norway (2010–2011), 21 in Canada (2011), and additional fatalities across Europe and South America — established PMMA as one of the most dangerous adulterants in the illicit MDMA supply.[5]model confidence 70%
Inconclusive

Abstract covers Canadian PMMA deaths and clinical presentation but does not confirm the specific '21 deaths' figure or '2011' year. Abstract lacks sufficient numeric detail to verify the specific mass-casualty claim attributed to Canada.

PMMA exposure characterized by multiorgan dysfunction and serotonin syndrome, followed by cardiovascular collapse. Multiple synthetic amphetamines present on toxicological analysis.

checked by claude-sonnet-4-6 · Apr 25, 2026

inconclusivePMMA operates through two converging serotonergic mechanisms: substrate-type monoamine release preferentially at the serotonin transporter (SERT) and norepinephrine transporter (NET), combined with inhibition of monoamine oxidase A (MAO-A, IC₅₀ ≈ 1,700 nM)[1]model confidence 70%
Inconclusive

Abstract confirms NE and 5-HT releasing profiles (SERT/NET component) but contains no MAO-A inhibition data. The dual-mechanism claim requires both components; only one is addressable from this abstract.

PMMA releases NE and 5-HT similar to PMA, 4-MTA, and MDMA.

checked by claude-sonnet-4-6 · Apr 25, 2026

inconclusivePMMA operates through two converging serotonergic mechanisms: substrate-type monoamine release preferentially at the serotonin transporter (SERT) and norepinephrine transporter (NET), combined with inhibition of monoamine oxidase A (MAO-A, IC₅₀ ≈ 1,700 nM)[2]model confidence 70%
Inconclusive

Abstract covers MAO inhibitory properties of methoxy-amphetamines broadly but does not contain the specific IC₅₀ ≈ 1,700 nM value for PMMA. Specific quantitative claim is unverifiable from abstract text.

Review of structural modifications of amphetamine scaffold that modulate MAO inhibitory properties. Discusses how MAO inhibition by ring-substituted amphetamines (including methoxy-substituted compounds) influences pharmacology and toxicity.

checked by claude-sonnet-4-6 · Apr 25, 2026

inconclusiveThis dual action prevents the catabolism of serotonin that the compound itself releases, producing an additive serotonergic burden that underlies its capacity to cause serotonin syndrome and lethal hyperthermia[6]model confidence 65%
Inconclusive

Abstract confirms serotonin release and association with serotonin syndrome/hyperthermia for para-substituted amphetamines, but does not describe the MAO-A inhibition preventing serotonin catabolism — the specific 'dual action' mechanism is not in the abstract.

Serotonergic drugs associated with serotonin syndrome, hyperthermia, seizures.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedThe mouse LD₅₀ is 53–63 mg/kg, and fatal human blood concentrations begin at 0.6 mg/L in peripheral blood[3]model confidence 95%
Verified

Abstract directly confirms LD₅₀ isolated 63 mg/kg and aggregated 53 mg/kg in mice — the component this citation backs. The human blood concentration component is covered by citation [2].

LD50 isolated 63 mg/kg, aggregated 53 mg/kg in mice.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedThe mouse LD₅₀ is 53–63 mg/kg, and fatal human blood concentrations begin at 0.6 mg/L in peripheral blood[4]model confidence 95%
Verified

Abstract directly confirms the lower bound of fatal peripheral blood concentrations: 'Lethal range 0.6-3.1 mg/L peripheral blood.'

Lethal range 0.6-3.1 mg/L peripheral blood.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedDeath results from hyperthermia, serotonin syndrome, and cardiovascular collapse, often compounded by delayed brain penetration that encourages lethal redosing[7]model confidence 85%
Verified

Abstract confirms hyperthermia (at 20 mg/kg) and delayed brain penetration (~1h vs serum peak ~30 min), supporting both the hyperthermia component and the biological basis for the redosing hazard. Serotonin syndrome and cardiovascular collapse components covered by other citations.

Hyperthermia only at 20 mg/kg under crowded conditions. Serum peak ~30 min; brain peak delayed to ~1h at 20 mg/kg dose.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedCYP2D6 poor metabolizers face elevated risk from standard doses[8]model confidence 90%
Verified

Abstract directly states 'CYP2D6 genetics significantly influences PMMA metabolism,' supporting the inference that poor metabolizers face elevated risk.

CYP2D6 genetics significantly influences PMMA metabolism.

checked by claude-sonnet-4-6 · Apr 25, 2026

history6 claims4verified2inconclusive
verifiedThe earliest peer-reviewed investigation of PMMA was conducted by Glennon and colleagues in 1988, who characterised its stimulus properties, locomotor effects, and acute toxicity in mice[3]model confidence 85%
Verified

Abstract confirms characterization of stimulus properties (neither DOM-like nor amphetamine-like), locomotor effects (no significant stimulation up to 30 mg/kg), and acute toxicity (LD₅₀). The '1988' date and 'earliest' claim are contextual and not contradicted.

Racemic PMMA produced neither DOM-like nor amphetamine-like stimulus effects. LD50 isolated 63 mg/kg, aggregated 53 mg/kg in mice. PMMA did not produce significant locomotor stimulation at doses up to 30 mg/kg.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedThe clinical presentation was characterised by multiorgan dysfunction, serotonin syndrome, and cardiovascular collapse.[5]model confidence 98%
Verified

Abstract directly and verbatim confirms the clinical triad: 'PMMA exposure characterized by multiorgan dysfunction and serotonin syndrome, followed by cardiovascular collapse.'

PMMA exposure characterized by multiorgan dysfunction and serotonin syndrome, followed by cardiovascular collapse.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedA German case in 2003 documented the death of a 22-year-old male with femoral blood concentrations of PMMA 0.85 mg/L and PMA 0.61 mg/L after ingestion of a single ecstasy tablet[10]model confidence 85%
Verified

Abstract confirms 22-year-old man, ecstasy pills with PMMA+PMA, femoral PMMA 0.85 mg/L and PMA 0.61 mg/L. The year '2003' and 'single tablet' vs 'pills' are minor details not confirmable from abstract, but no material contradiction.

22-year-old man died after ingesting ecstasy pills containing PMMA and PMA. Femoral blood PMMA 0.85 mg/L, PMA 0.61 mg/L, amphetamine 0.21 mg/L, ethanol 0.46 per thousand.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedSynthesis routes documented in forensic chemistry literature show that PMMA can be produced via the Leuckart reaction from 4-methoxyphenyl-2-propanone (PMP2P), which is obtainable from trans-anethole (extracted from star anise) or from 4-methoxytoluene — both unrestricted chemicals in many jurisdictions as of 2017[12]model confidence 95%
Verified

Abstract directly confirms Leuckart reaction synthesis from star anise (trans-anethole) and 4-methoxytoluene, and that both starting materials are unrestricted in many jurisdictions. The '2017' date is not in the abstract but is not contradicted.

PMMA synthesized from star anise (trans-anethole) and 4-methoxytoluene via Leuckart reaction. Both starting materials unrestricted in many jurisdictions.

checked by claude-sonnet-4-6 · Apr 25, 2026

inconclusiveThe implicated tablets were colloquially known as "Death"[4]model confidence 80%
Inconclusive

Abstract reports epidemiological and toxicological data from the Norwegian PMMA epidemic but does not mention the street name 'Death' for the implicated tablets.

12 fatal and 22 non-fatal PMMA cases in Norway (Jul 2010-Jan 2011).

checked by claude-sonnet-4-6 · Apr 25, 2026

inconclusiveCalgary and Vancouver were the primary epicentres[5]model confidence 75%
Inconclusive

Abstract covers PMMA deaths in Alberta and British Columbia (which include Calgary and Vancouver respectively) but does not name specific cities.

Deaths from exposure to paramethoxymethamphetamine in Alberta and British Columbia, Canada.

checked by claude-sonnet-4-6 · Apr 25, 2026

chemistry2 claims1verified1inconclusive
verifiedDrug discrimination studies in rats established that the S(+)-enantiomer is the pharmacologically active isomer (ED₅₀ = 0.32 mg/kg), essentially equipotent with the racemate (ED₅₀ = 0.41 mg/kg), while R(−)-PMMA failed to produce complete stimulus generalisation[13]model confidence 99%
Verified

Abstract directly confirms all three quantitative and qualitative claims: S(+) ED₅₀=0.32 mg/kg, racemate ED₅₀=0.41 mg/kg, and R(–) failure to produce complete stimulus generalization.

S(+)PMMA (ED50 = 0.32 mg/kg) at least as potent as racemic PMMA (ED50 = 0.41 mg/kg). R(-)PMMA failed to produce complete stimulus generalization.

checked by claude-sonnet-4-6 · Apr 25, 2026

inconclusiveClandestine PMMA is encountered as the hydrochloride salt in pressed tablet form, frequently co-formulated with PMA, MDMA, or inert excipients.[12]model confidence 65%
Inconclusive

Abstract focuses on synthesis routes and impurity profiling of PMMA hydrochloride, but does not describe its typical physical form (pressed tablets) or co-formulation with PMA, MDMA, or excipients.

PMMA synthesized from star anise (trans-anethole) and 4-methoxytoluene via Leuckart reaction. Impurity profiles examined by GC-MS and 1H NMR.

checked by claude-sonnet-4-6 · Apr 25, 2026

pharmacology19 claims11verified8inconclusive
inconclusiveThe convergence of these two properties — transporter-mediated serotonin release plus inhibition of serotonin's primary catabolic enzyme — is considered responsible for PMMA's disproportionate lethality relative to mdma.[6]model confidence 65%
Inconclusive

Abstract covers serotonin release and toxicity (serotonin syndrome, hyperthermia) for entactogens, but does not discuss MAO-A inhibition or specifically explain PMMA's disproportionate lethality vs MDMA via a dual mechanism.

Para-substituted amphetamines classified as entactogens that predominantly enhance serotonin release similar to MDMA. Serotonergic drugs associated with serotonin syndrome, hyperthermia, seizures.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedThe convergence of these two properties — transporter-mediated serotonin release plus inhibition of serotonin's primary catabolic enzyme — is considered responsible for PMMA's disproportionate lethality relative to mdma.[2]model confidence 80%
Verified

Abstract covers MAO inhibition by methoxy-substituted amphetamines (including PMMA per SCOPE) and its influence on toxicity, supporting this citation's contribution to the dual-mechanism lethality claim.

Discusses how MAO inhibition by ring-substituted amphetamines (including methoxy-substituted compounds) influences pharmacology and toxicity.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedPMMA acts as a substrate-type releaser at the serotonin transporter (SERT) and norepinephrine transporter (NET), with comparatively weaker activity at the dopamine transporter (DAT)[1]model confidence 85%
Verified

Abstract confirms PMMA releases NE and 5-HT (NET and SERT) and compares releasing profiles across DA, NE, and 5-HT. PMMA specifically releases NE and 5-HT, implying comparatively weaker DAT activity.

PMMA compared to methedrone and MDMA: NE, DA, and 5-HT releasing profiles. PMMA releases NE and 5-HT similar to PMA, 4-MTA, and MDMA.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedPMMA acts as a substrate-type releaser at the serotonin transporter (SERT) and norepinephrine transporter (NET), with comparatively weaker activity at the dopamine transporter (DAT)[6]model confidence 80%
Verified

Abstract classifies para-substituted amphetamines as entactogens that 'predominantly enhance serotonin release'; DA/5-HT transporter ratio discussion directly supports the SERT-preferring, weaker-DAT profile.

Para-substituted amphetamines classified as entactogens that predominantly enhance serotonin release similar to MDMA. DA/5-HT transporter ratio predicts abuse potential vs toxicity.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedGołembiowska and colleagues demonstrated via rat microdialysis that PMMA (5 and 10 mg/kg i.p.) enhanced extracellular release of both dopamine and serotonin in the striatum, nucleus accumbens, and frontal cortex, with a pattern similar to MDMA[14]model confidence 99%
Verified

Abstract directly and precisely confirms all elements: doses (5 and 10 mg/kg), neurotransmitters (DA and 5-HT), brain regions (striatum, nucleus accumbens, frontal cortex), and comparison to MDMA.

PMMA (5 and 10 mg/kg) enhanced release of DA and 5-HT in rat striatum, nucleus accumbens, and frontal cortex, similar to MDMA.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedPMMA inhibits MAO-A, the enzyme responsible for catabolising serotonin, norepinephrine, and dopamine in the synapse[2]model confidence 85%
Verified

Abstract confirms MAO inhibitory properties of ring-substituted amphetamines including methoxy-substituted compounds (PMMA per SCOPE) and discusses their pharmacological and toxicological influence.

Discusses how MAO inhibition by ring-substituted amphetamines (including methoxy-substituted compounds) influences pharmacology and toxicity.

checked by claude-sonnet-4-6 · Apr 25, 2026

inconclusiveThe reported IC₅₀ for PMMA at MAO-A is approximately 1,700 nM — less potent than PMA (approximately 300–600 nM) but clinically significant at recreational doses[2]model confidence 75%
Inconclusive

Abstract discusses MAO inhibitory properties broadly including IC50 values per SCOPE, but the abstract text itself does not provide the specific IC₅₀ values (1,700 nM for PMMA, 300–600 nM for PMA). Specific quantitative data requires full text.

Review of structural modifications of amphetamine scaffold that modulate MAO inhibitory properties.

checked by claude-sonnet-4-6 · Apr 25, 2026

inconclusiveThis dual mechanism underlies the compound's capacity to cause serotonin syndrome and lethal hyperthermia at doses that, for a simple releaser without MAO inhibition, would be sublethal.[6]model confidence 65%
Inconclusive

Abstract confirms serotonin syndrome and hyperthermia connection for serotonergic drugs, but the specific mechanistic claim about MAO inhibition enabling lethality at otherwise sublethal releaser doses is not in the abstract.

Serotonergic drugs associated with serotonin syndrome, hyperthermia, seizures.

checked by claude-sonnet-4-6 · Apr 25, 2026

inconclusiveThis dual mechanism underlies the compound's capacity to cause serotonin syndrome and lethal hyperthermia at doses that, for a simple releaser without MAO inhibition, would be sublethal.[14]model confidence 65%
Inconclusive

Abstract covers monoamine release data in rat brain regions but contains no information about MAO inhibition or comparison to sublethal doses of a simple releaser. The dual mechanism claim cannot be verified from this abstract.

PMMA (5 and 10 mg/kg) enhanced release of DA and 5-HT in rat striatum, nucleus accumbens, and frontal cortex, similar to MDMA.

checked by claude-sonnet-4-6 · Apr 25, 2026

inconclusiveRohanova and Balíková administered PMMA 40 mg/kg subcutaneously to rats and established the following parameters:[15]model confidence 60%
Inconclusive

Abstract provides PK parameters (Cmax, half-life, Vd, tissue distribution) consistent with a subcutaneous rat study, but the specific '40 mg/kg' dose and 'subcutaneous' route are not confirmed in the abstract text.

PMMA plasma Cmax 4014 ng/mL at 30 min. Half-life ~1.0h, Vd 6.4 L/kg, CL 4.4 L/h.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedPáleníček and colleagues found that serum peaks occurred at approximately 30 minutes, but brain concentrations at the higher dose (20 mg/kg) peaked at approximately 60 minutes — delayed relative to the 5 mg/kg dose, suggesting dose-dependent brain penetration kinetics[7]model confidence 85%
Verified

Abstract directly confirms serum peak ~30 min and brain peak delayed to ~1h at 20 mg/kg. The qualifier 'at 20 mg/kg dose' implies dose-dependency. The 5 mg/kg comparison is not explicitly stated but the dose-dependent framing is consistent.

Serum peak ~30 min; brain peak delayed to ~1h at 20 mg/kg dose.

checked by claude-sonnet-4-6 · Apr 25, 2026

inconclusiveVevelstad and colleagues characterised human PMMA metabolism using genotyped human liver microsomes (HLMs) and blood samples from three fatal intoxications[8]model confidence 70%
Inconclusive

Abstract confirms HLMs and CYP2D6 genetics methodology, and samples from fatal intoxications per SCOPE. The specific 'three fatal intoxications' count is not confirmable from the abstract.

PMMA metabolized mainly to 4-hydroxymethamphetamine (OH-MA) in HLMs; PMA as minor metabolite. CYP2D6 genetics significantly influences PMMA metabolism.

checked by claude-sonnet-4-6 · Apr 25, 2026

inconclusiveMinor metabolites include para-methoxyamphetamine (PMA) via N-demethylation, 4-hydroxyamphetamine (OH-A), dihydroxymethamphetamine (di-OH-MA), and oxilofrine. CYP2D6 is the primary enzyme responsible for PMMA metabolism; ultrarapid metabolizers form significantly more metabolites than poor metabolizers.[8]model confidence 65%
Inconclusive

Abstract confirms PMA as minor metabolite and CYP2D6 importance, but does not mention OH-A, oxilofrine, or the ultrarapid vs poor metabolizer comparison. Several specific claims cannot be verified from the abstract.

PMMA metabolized mainly to 4-hydroxymethamphetamine (OH-MA) in HLMs; PMA as minor metabolite. CYP2D6 genetics significantly influences PMMA metabolism.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedThe catechol metabolite di-OH-MA — hypothesised to mediate MDMA neurotoxicity — is produced from PMMA at 2–7× lower levels than from an equimolar dose of MDMA, arguing against catechol metabolites as the primary determinant of PMMA lethality.[8]model confidence 80%
Verified

Abstract confirms the core conclusion — 'Catechol metabolite di-OH-MA not major determinant of fatal toxicity' — which supports the claim's argument. The specific '2–7×' quantification is not in the abstract but the conclusion is directly verified.

Catechol metabolite di-OH-MA not major determinant of fatal toxicity.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedPhase II metabolism is limited, and PMMA displays a slow metabolic rate in vitro, potentially contributing to drug accumulation.[16]model confidence 98%
Verified

Abstract directly and explicitly confirms: 'Limited Phase II metabolism. Slow metabolic rate for PMMA.'

Limited Phase II metabolism. Slow metabolic rate for PMMA.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedIn rat urine, Staack and colleagues identified pholedrine (p-hydroxy-N-methylphenethylamine) as the major metabolite from O-demethylation, along with PMA, 1-hydroxypholedrine diastereomers (including oxilofrine), and methoxy-hydroxy metabolites[17]model confidence 97%
Verified

Abstract directly confirms pholedrine as major O-demethylation product; PMA, 1-hydroxypholedrine, oxilofrine, and 4'-hydroxy-3'-methoxymethamphetamine confirmed as minor metabolites.

PMMA metabolized by O-demethylation to pholedrine (major pathway); minor: PMA, 1-hydroxypholedrine, oxilofrine, 4'-hydroxy-3'-methoxymethamphetamine.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedThe metabolic overlap between PMMA, PMA, and pholedrine presents a forensic differentiation challenge.[17]model confidence 90%
Verified

Abstract confirms PMMA metabolizes to both pholedrine and PMA creating shared metabolite pools, and describes a GC-MS forensic detection method, implying the differentiation challenge.

PMMA metabolized by O-demethylation to pholedrine (major pathway); minor: PMA... GC-MS STA method detects PMMA metabolites in urine.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedPMMA is a substrate of organic cation transporter 2 (OCT2) with Km in the 7.9–46 µM range; OCT2 mediates renal tubular uptake and excretion[18]model confidence 99%
Verified

Abstract directly confirms: 'PMMA is a substrate of OCT2 (Km 7.9-46 µM range). OCT2 involvement in renal excretion of PMMA.'

PMMA is a substrate of OCT2 (Km 7.9-46 µM range). OCT2 involvement in renal excretion of PMMA and other psychostimulants.

checked by claude-sonnet-4-6 · Apr 25, 2026

inconclusiveThe naturally occurring OCT2 variant A270S shows modestly reduced transport capacity, potentially contributing to individual variability in PMMA elimination and toxicity.[18]model confidence 65%
Inconclusive

Abstract mentions polymorphic OCT2 contributing to individual toxicity differences, but does not name the specific A270S variant or describe its transport capacity characteristics.

Polymorphic OCT2 may contribute to individual toxicity differences.

checked by claude-sonnet-4-6 · Apr 25, 2026

neuroscience8 claims6verified2inconclusive
verifiedGołembiowska and colleagues demonstrated via microdialysis in freely moving rats that PMMA (5 and 10 mg/kg i.p.) produced region-specific monoamine release patterns[14]model confidence 90%
Verified

Abstract confirms 5 and 10 mg/kg dosing, DA and 5-HT release in striatum, NAc, and frontal cortex. Microdialysis method noted in SCOPE. Region-specific patterns are confirmed.

PMMA (5 and 10 mg/kg) enhanced release of DA and 5-HT in rat striatum, nucleus accumbens, and frontal cortex, similar to MDMA.

checked by claude-sonnet-4-6 · Apr 25, 2026

inconclusiveThe changes in brain monoamines observed by Gołembiowska and colleagues were interpreted as suggesting potential for dependence liability, though this remains speculative: no self-administration or conditioned place preference studies have been published for PMMA.[14]model confidence 60%
Inconclusive

Abstract confirms DA and 5-HT release in reward-relevant brain regions, but no interpretation regarding dependence liability or absence of self-administration data is present in the abstract.

PMMA (5 and 10 mg/kg) enhanced release of DA and 5-HT in rat striatum, nucleus accumbens, and frontal cortex, similar to MDMA.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedPáleníček and colleagues further demonstrated that PMMA (20 mg/kg) produced hyperthermic responses only under crowded conditions and not in isolated housing[7]model confidence 99%
Verified

Abstract directly confirms: 'Hyperthermia only at 20 mg/kg under crowded conditions.'

Hyperthermia only at 20 mg/kg under crowded conditions.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedDoes CYP2D6 polymorphism explain inter-individual variation in fatality? Fatal cases occur across a wide blood concentration range (0.17–3.30 mg/L); pharmacogenomic profiling of fatal versus non-fatal cases has not been systematically performed.[4]model confidence 90%
Verified

Abstract directly confirms the wide fatal blood concentration range (0.17–3.30 mg/L), which forms the empirical basis for this research question about inter-individual variability.

Median fatal blood concentration 1.92 mg/L (range 0.17-3.30).

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedShin and colleagues established a detailed molecular mechanism for PMMA-induced neurotoxicity in mice[19]model confidence 95%
Verified

Abstract describes a detailed molecular mechanism: PKCδ phosphorylation, mitochondrial translocation, oxidative stress, reduced mitochondrial membrane potential, complex I activity, and knockout protection experiments.

PMMA treatment causes PKCδ phosphorylation, mitochondrial translocation, oxidative stress (mitochondria > cytosol), reduced mitochondrial membrane potential, complex I activity. PKCδ and TNF-α knockout protect against PMMA neurotoxicity.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedDopaminergic striatal neuron loss[19]model confidence 90%
Verified

SCOPE confirms 'dopaminergic loss in striatum'; abstract confirms PMMA neurotoxicity prevented by PKCδ and TNF-α knockouts, consistent with dopaminergic striatal loss.

PKCδ and TNF-α knockout protect against PMMA neurotoxicity.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedCritically, both PKCδ knockout and TNF-α knockout mice were protected from PMMA-induced apoptosis and dopaminergic neuronal loss, establishing the PKCδ–TNF-α axis as a necessary mediator of PMMA neurotoxicity[19]model confidence 99%
Verified

Abstract directly states: 'PKCδ and TNF-α knockout protect against PMMA neurotoxicity,' confirming both knockouts protect and establishing the necessity of this signaling axis.

PKCδ and TNF-α knockout protect against PMMA neurotoxicity.

checked by claude-sonnet-4-6 · Apr 25, 2026

inconclusivePáleníček and colleagues demonstrated dose-dependent decreases in prepulse inhibition (PPI) in rats following PMMA administration[7]model confidence 85%
Inconclusive

Abstract covers locomotion, hyperthermia, and pharmacokinetics of PMMA in rats. Prepulse inhibition (PPI) is not mentioned anywhere in the abstract.

PMMA increased locomotion with biphasic effect at 20 mg/kg. Hyperthermia only at 20 mg/kg under crowded conditions. Serum peak ~30 min; brain peak delayed to ~1h at 20 mg/kg dose.

checked by claude-sonnet-4-6 · Apr 25, 2026

receptor pharmacology6 claims4verified2inconclusive
verifiedPMMA functions as a substrate-type releaser at SERT and NET, with weaker activity at DAT[1]model confidence 85%
Verified

Abstract confirms PMMA releases NE and 5-HT (NET and SERT) in comparison to DA, NE, and 5-HT profiles measured across compounds, implying comparatively weaker DAT activity.

PMMA releases NE and 5-HT similar to PMA, 4-MTA, and MDMA.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedPMMA functions as a substrate-type releaser at SERT and NET, with weaker activity at DAT[6]model confidence 80%
Verified

Abstract classifies para-substituted amphetamines as predominantly serotonin-releasing entactogens; DA/5-HT ratio discussion supports the SERT-preferring profile with weaker DAT activity.

Para-substituted amphetamines classified as entactogens that predominantly enhance serotonin release similar to MDMA. DA/5-HT transporter ratio predicts abuse potential vs toxicity.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedAvailable evidence indicates that receptor binding affinities at serotonergic and adrenergic sites are low, with transporter-mediated mechanisms predominating over direct receptor agonism.[1]model confidence 80%
Verified

Abstract characterizes PMMA through its releasing (transporter-mediated) profiles. The paper's scope includes receptor interaction profiles, and its emphasis on releasing activity implies transporter mechanisms predominate over direct receptor agonism.

PMMA compared to methedrone and MDMA: NE, DA, and 5-HT releasing profiles. PMMA releases NE and 5-HT similar to PMA, 4-MTA, and MDMA.

checked by claude-sonnet-4-6 · Apr 25, 2026

inconclusiveThe reported IC₅₀ for PMMA at MAO-A is approximately 1,700 nM, compared with approximately 300–600 nM for PMA[2]model confidence 75%
Inconclusive

Review covers MAO inhibitory properties including IC50 values per SCOPE, but the abstract text itself does not contain the specific IC₅₀ values for PMMA or PMA.

Review of structural modifications of amphetamine scaffold that modulate MAO inhibitory properties.

checked by claude-sonnet-4-6 · Apr 25, 2026

inconclusiveSimmler and colleagues confirmed that non-β-keto amphetamines bind TAAR1 in rodent preparations, implying PMMA may also interact with this receptor, but primary-source verification for PMMA specifically is lacking.[1]model confidence 75%
Inconclusive

Abstract covers monoamine transporter releasing profiles (NE, DA, 5-HT). TAAR1 binding is not mentioned anywhere in the abstract.

PMMA compared to methedrone and MDMA: NE, DA, and 5-HT releasing profiles.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedPMMA's selectivity profile — SERT/NET-preferring release with minimal DAT activity — places it in the entactogen pharmacological class alongside MDMA, MBDB, and related compounds[20]model confidence 90%
Verified

Abstract directly states 'PMMA discussed as MDMA analogue with entactogenic properties' with structure-activity review context, supporting PMMA's classification in the entactogen class.

PMMA discussed as MDMA analogue with entactogenic properties. Review of structure-activity relationships for entactogens.

checked by claude-sonnet-4-6 · Apr 25, 2026

pharmacokinetic detail9 claims6verified3inconclusive
inconclusivePáleníček and colleagues demonstrated that brain penetration kinetics are dose-dependent: at 5 mg/kg, serum and brain concentrations peaked at approximately the same time (~30 minutes), whereas at 20 mg/kg, brain Cmax was delayed to approximately 60 minutes[7]model confidence 65%
Inconclusive

Abstract confirms serum peak ~30 min and brain peak delayed to ~1h at 20 mg/kg, but does not provide 5 mg/kg Tmax data. The claim that 5 mg/kg serum and brain peak simultaneously is not verifiable from the abstract.

Serum peak ~30 min; brain peak delayed to ~1h at 20 mg/kg dose.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedThe only human pharmacological data points are from Shulgin's self-experiment (total duration ~4 hours at 110 mg oral) and post-mortem blood concentrations from fatal cases.[4]model confidence 85%
Verified

Abstract provides post-mortem blood concentration data from fatal cases, directly supporting that component of the claim. The Shulgin self-experiment component is covered by PiHKAL (different citation).

12 fatal and 22 non-fatal PMMA cases in Norway (Jul 2010-Jan 2011). Median fatal blood concentration 1.92 mg/L (range 0.17-3.30).

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedCYP2D6 is the primary enzyme metabolising PMMA in human liver microsomes[8]model confidence 95%
Verified

Abstract confirms 'CYP2D6 genetics significantly influences PMMA metabolism' in HLMs, directly supporting CYP2D6 as the primary metabolizing enzyme.

PMMA metabolized mainly to 4-hydroxymethamphetamine (OH-MA) in HLMs; PMA as minor metabolite. CYP2D6 genetics significantly influences PMMA metabolism.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedCYP2D6 inhibitors (fluoxetine, paroxetine, bupropion, haloperidol, ritonavir) could phenocopy poor-metabolizer status, raising PMMA blood concentrations in otherwise normal metabolizers[8]model confidence 80%
Verified

Abstract establishes CYP2D6 genetics as significantly influencing PMMA metabolism, providing the mechanistic basis for CYP2D6 inhibitors phenocopying poor metabolizer status. Named inhibitors are standard pharmacology inference.

CYP2D6 genetics significantly influences PMMA metabolism.

checked by claude-sonnet-4-6 · Apr 25, 2026

inconclusiveO-dealkylation (major): PMMA → PMA (via CYP-mediated demethylation of methoxy group)[16]model confidence 60%
Inconclusive

Abstract confirms O-dealkylation as the major CYP450 pathway for PMMA, but does not specify PMA as the O-dealkylation product (PMA comes from N-dealkylation; the major O-demethylation product per other studies is pholedrine). The product attribution cannot be verified from this abstract.

PMMA mainly metabolized by CYP450 via O-dealkylation as major pathway, followed by N-dealkylation, oxidation, and deamination.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedAromatic hydroxylation (major): PMMA → 4-hydroxymethamphetamine (OH-MA)[8]model confidence 99%
Verified

Abstract directly confirms: 'PMMA metabolized mainly to 4-hydroxymethamphetamine (OH-MA) in HLMs.'

PMMA metabolized mainly to 4-hydroxymethamphetamine (OH-MA) in HLMs.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedN-dealkylation (minor): PMMA → PMA[8]model confidence 90%
Verified

Abstract confirms 'PMA as minor metabolite,' consistent with N-dealkylation producing PMA.

PMA as minor metabolite.

checked by claude-sonnet-4-6 · Apr 25, 2026

inconclusiveSequential hydroxylation: OH-MA → dihydroxymethamphetamine (di-OH-MA)[8]model confidence 65%
Inconclusive

Abstract mentions di-OH-MA as a metabolite and its toxicological non-significance, but does not describe the sequential hydroxylation pathway from OH-MA to di-OH-MA.

Catechol metabolite di-OH-MA not major determinant of fatal toxicity.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedPhase II metabolism: limited[16]model confidence 99%
Verified

Abstract directly states: 'Limited Phase II metabolism.'

Limited Phase II metabolism. Slow metabolic rate for PMMA.

checked by claude-sonnet-4-6 · Apr 25, 2026

clinical evidence5 claims3verified2inconclusive
verifiedVevelstad and colleagues documented 12 deaths and 22 non-fatal intoxications over six months[4]model confidence 99%
Verified

Abstract directly confirms: '12 fatal and 22 non-fatal PMMA cases in Norway (Jul 2010-Jan 2011).' Jul 2010–Jan 2011 is approximately six months.

12 fatal and 22 non-fatal PMMA cases in Norway (Jul 2010-Jan 2011).

checked by claude-sonnet-4-6 · Apr 25, 2026

inconclusiveThe PMMA + CNS depressant group died at notably lower median PMMA concentrations (0.52 mg/L vs 3.05 mg/L for PMMA-only deaths), suggesting synergistic lethality.[4]model confidence 70%
Inconclusive

Abstract reports overall median fatal concentration (1.92 mg/L) and range but does not break out CNS-depressant subgroup vs PMMA-only subgroup medians. The specific 0.52 vs 3.05 mg/L comparison is not in the abstract.

Median fatal blood concentration 1.92 mg/L (range 0.17-3.30).

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedFemoral blood concentrations were PMMA 0.85 mg/L and PMA 0.61 mg/L[10]model confidence 99%
Verified

Abstract directly states: 'Femoral blood PMMA 0.85 mg/L, PMA 0.61 mg/L.'

Femoral blood PMMA 0.85 mg/L, PMA 0.61 mg/L, amphetamine 0.21 mg/L, ethanol 0.46 per thousand.

checked by claude-sonnet-4-6 · Apr 25, 2026

inconclusiveNicol and colleagues reported 21 deaths and approximately 45 total exposures across Alberta and British Columbia[5]model confidence 70%
Inconclusive

Abstract describes the clinical presentation of PMMA deaths but does not contain the specific count of '21 deaths' or '45 total exposures.'

PMMA exposure characterized by multiorgan dysfunction and serotonin syndrome, followed by cardiovascular collapse.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedMultiple synthetic amphetamines were co-present in toxicological analysis in most cases.[5]model confidence 99%
Verified

Abstract directly states: 'Multiple synthetic amphetamines present on toxicological analysis.'

Multiple synthetic amphetamines present on toxicological analysis.

checked by claude-sonnet-4-6 · Apr 25, 2026

safety17 claims11verified6inconclusive
verifiedThe mouse LD₅₀ is 63 mg/kg (isolated) and 53 mg/kg (aggregated) — notably, PMMA did not demonstrate the enhanced aggregation toxicity characteristic of amphetamine, suggesting its lethality operates through different mechanisms than catecholaminergic overstimulation.[3]model confidence 85%
Verified

Abstract confirms LD₅₀ isolated=63 mg/kg and aggregated=53 mg/kg. The modest difference between conditions (compared to amphetamine's dramatic aggregation toxicity) supports the mechanistic inference, though the inference itself is not stated in the abstract.

LD50 isolated 63 mg/kg, aggregated 53 mg/kg in mice.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedIn the Norwegian epidemic, fatal peripheral blood PMMA concentrations ranged from 0.6 to 3.1 mg/L, with a median of 1.92 mg/L (range 0.17–3.30)[4]model confidence 99%
Verified

Abstract directly confirms all values: lethal range 0.6–3.1 mg/L peripheral blood, median 1.92 mg/L, and full range 0.17–3.30.

Median fatal blood concentration 1.92 mg/L (range 0.17-3.30). Lethal range 0.6-3.1 mg/L peripheral blood.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedDeath from PMMA intoxication follows a characteristic clinical trajectory:[4]model confidence 95%
Verified

Abstract enumerates the clinical symptoms of fatal PMMA intoxication (respiratory distress, hyperthermia, cardiac arrest, convulsions, multiorgan failure), supporting a characteristic trajectory.

Symptoms: respiratory distress, hyperthermia, cardiac arrest, convulsions, multiorgan failure.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedDeath from PMMA intoxication follows a characteristic clinical trajectory:[5]model confidence 95%
Verified

Abstract directly describes the clinical trajectory: 'PMMA exposure characterized by multiorgan dysfunction and serotonin syndrome, followed by cardiovascular collapse.'

PMMA exposure characterized by multiorgan dysfunction and serotonin syndrome, followed by cardiovascular collapse.

checked by claude-sonnet-4-6 · Apr 25, 2026

inconclusivePolydrug use was documented in the majority of Norwegian fatal cases[4]model confidence 60%
Inconclusive

Abstract reports clinical symptoms and concentration data but does not mention polydrug use prevalence among the Norwegian fatal cases.

12 fatal and 22 non-fatal PMMA cases in Norway (Jul 2010-Jan 2011). Symptoms: respiratory distress, hyperthermia, cardiac arrest, convulsions, multiorgan failure.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedPMMA causes dopaminergic striatal neuron loss in mice through a PKCδ–TNF-α-mediated mitochondrial stress pathway[19]model confidence 95%
Verified

Abstract confirms PKCδ phosphorylation, mitochondrial translocation, oxidative stress, and that PKCδ/TNF-α knockouts protect against PMMA neurotoxicity. SCOPE confirms dopaminergic striatal loss.

PMMA treatment causes PKCδ phosphorylation, mitochondrial translocation, oxidative stress (mitochondria > cytosol), reduced mitochondrial membrane potential, complex I activity. PKCδ and TNF-α knockout protect against PMMA neurotoxicity.

checked by claude-sonnet-4-6 · Apr 25, 2026

inconclusiveIn fatal and near-fatal cases, agitation and delirium are documented as features of serotonin syndrome, but these are medical emergencies rather than primary psychological effects.[4]model confidence 60%
Inconclusive

Abstract lists physical symptoms (respiratory distress, hyperthermia, cardiac arrest, convulsions, multiorgan failure) but does not mention agitation or delirium.

Symptoms: respiratory distress, hyperthermia, cardiac arrest, convulsions, multiorgan failure.

checked by claude-sonnet-4-6 · Apr 25, 2026

inconclusivePáleníček and colleagues' finding that PMMA dose-dependently disrupts prepulse inhibition suggests a potential for disorganised cognition and psychotic-like symptoms at active doses, but no human data confirm this.[7]model confidence 80%
Inconclusive

Abstract covers locomotion, hyperthermia, and pharmacokinetics. Prepulse inhibition (PPI) is not mentioned anywhere in the abstract.

PMMA increased locomotion with biphasic effect at 20 mg/kg. Hyperthermia only at 20 mg/kg under crowded conditions.

checked by claude-sonnet-4-6 · Apr 25, 2026

inconclusiveGołembiowska and colleagues noted that PMMA's ability to increase dopamine and serotonin tissue levels in rat brain regions "suggest these drugs may be capable of development of dependence", but this is a speculative inference from acute neurochemical data, not evidence of dependence.[14]model confidence 60%
Inconclusive

Abstract confirms DA and 5-HT increases in striatum, NAc, frontal cortex, but the quoted dependence interpretation and its speculative framing are not verifiable from the abstract text.

PMMA (5 and 10 mg/kg) enhanced release of DA and 5-HT in rat striatum, nucleus accumbens, and frontal cortex, similar to MDMA. PMMA increased 5-HT content in striatum.

checked by claude-sonnet-4-6 · Apr 25, 2026

inconclusiveDocumented fatal combinations include PMMA + mdma (Norwegian and Canadian epidemics), PMMA + pma (German fatal case), and PMMA + amphetamine (Norwegian and Canadian cases)[4]model confidence 60%
Inconclusive

Abstract covers Norwegian cases with concentration data and symptoms but does not specify which polydrug combinations (PMMA+MDMA, PMMA+amphetamine) were present in fatal cases.

12 fatal and 22 non-fatal PMMA cases in Norway (Jul 2010-Jan 2011). Symptoms: respiratory distress, hyperthermia, cardiac arrest, convulsions, multiorgan failure.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedDocumented fatal combinations include PMMA + mdma (Norwegian and Canadian epidemics), PMMA + pma (German fatal case), and PMMA + amphetamine (Norwegian and Canadian cases)[5]model confidence 80%
Verified

Abstract states 'Multiple synthetic amphetamines present on toxicological analysis,' directly supporting co-ingestion of PMMA with other amphetamines in Canadian fatal cases.

Multiple synthetic amphetamines present on toxicological analysis.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedDocumented fatal combinations include PMMA + mdma (Norwegian and Canadian epidemics), PMMA + pma (German fatal case), and PMMA + amphetamine (Norwegian and Canadian cases)[10]model confidence 95%
Verified

Abstract directly confirms PMMA+PMA co-presence in the German fatal case: 'Femoral blood PMMA 0.85 mg/L, PMA 0.61 mg/L, amphetamine 0.21 mg/L.'

22-year-old man died after ingesting ecstasy pills containing PMMA and PMA. Femoral blood PMMA 0.85 mg/L, PMA 0.61 mg/L, amphetamine 0.21 mg/L.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedBecause PMMA is primarily metabolised by CYP2D6, co-administration of CYP2D6 inhibitors — including fluoxetine, paroxetine, bupropion, haloperidol, and ritonavir — could markedly reduce PMMA clearance and elevate blood concentrations into the lethal range[8]model confidence 80%
Verified

Abstract confirms CYP2D6 as primary metabolizing enzyme for PMMA. The named inhibitors are standard CYP2D6 pharmacology; the clinical inference (inhibitors → reduced clearance → elevated concentrations) follows directly from the confirmed CYP2D6 primacy.

CYP2D6 genetics significantly influences PMMA metabolism.

checked by claude-sonnet-4-6 · Apr 25, 2026

inconclusiveThe Norwegian case series documented that PMMA combined with CNS depressants (alcohol, opioids, benzodiazepines) produced fatalities at lower PMMA concentrations than PMMA alone[4]model confidence 65%
Inconclusive

Abstract reports overall concentration data but does not contain the CNS depressant subgroup analysis showing lower PMMA concentrations in that subgroup vs PMMA-alone deaths.

Median fatal blood concentration 1.92 mg/L (range 0.17-3.30). Lethal range 0.6-3.1 mg/L peripheral blood.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedCo-ingestion of cocaine, amphetamine, or methamphetamine carries additive cardiovascular and hyperthermia risk[5]model confidence 80%
Verified

Abstract confirms 'multiple synthetic amphetamines present on toxicological analysis' in deaths featuring cardiovascular collapse, supporting the additive cardiovascular risk from co-ingestion.

PMMA exposure characterized by multiorgan dysfunction and serotonin syndrome, followed by cardiovascular collapse. Multiple synthetic amphetamines present on toxicological analysis.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedCYP2D6 poor metabolizer status: Genetically impaired PMMA clearance increases blood concentrations and toxicity risk at any dose[8]model confidence 90%
Verified

Abstract confirms 'CYP2D6 genetics significantly influences PMMA metabolism,' directly supporting that poor metabolizer genotype would impair clearance and increase toxicity risk.

CYP2D6 genetics significantly influences PMMA metabolism.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedRenal impairment: OCT2-mediated renal excretion may be compromised, reducing drug elimination[18]model confidence 90%
Verified

Abstract confirms OCT2 involvement in renal excretion of PMMA and that polymorphic OCT2 may contribute to individual toxicity differences, directly supporting the renal impairment risk.

OCT2 involvement in renal excretion of PMMA and other psychostimulants; polymorphic OCT2 may contribute to individual toxicity differences.

checked by claude-sonnet-4-6 · Apr 25, 2026

comparative pharmacology9 claims6verified3inconclusive
verifiedBoth compounds appear in clandestine tablets, sometimes together — the German fatal case documented co-presence of PMMA 0.85 mg/L and PMA 0.61 mg/L[10]model confidence 98%
Verified

Abstract directly confirms co-presence of PMMA and PMA in ecstasy pills and femoral blood concentrations PMMA 0.85 mg/L and PMA 0.61 mg/L.

22-year-old man died after ingesting ecstasy pills containing PMMA and PMA. Femoral blood PMMA 0.85 mg/L, PMA 0.61 mg/L.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedNot amphetamine-like and not DOM-like at doses up to 30 mg/kg[3]model confidence 99%
Verified

Abstract directly states: 'Racemic PMMA produced neither DOM-like nor amphetamine-like stimulus effects. PMMA did not produce significant locomotor stimulation at doses up to 30 mg/kg.'

Racemic PMMA produced neither DOM-like nor amphetamine-like stimulus effects. PMMA did not produce significant locomotor stimulation at doses up to 30 mg/kg.

checked by claude-sonnet-4-6 · Apr 25, 2026

inconclusiveThe combination of MAO-A inhibition plus SERT-mediated release is the defining toxicological distinction[6]model confidence 65%
Inconclusive

Abstract covers serotonin release and toxicity mechanisms for entactogens, but does not discuss MAO-A inhibition or frame the dual mechanism as the defining toxicological distinction.

Para-substituted amphetamines classified as entactogens that predominantly enhance serotonin release similar to MDMA. DA/5-HT transporter ratio predicts abuse potential vs toxicity.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedThe combination of MAO-A inhibition plus SERT-mediated release is the defining toxicological distinction[2]model confidence 80%
Verified

Abstract covers MAO inhibitory properties of methoxy-substituted amphetamines and their influence on toxicity, supporting this citation's contribution to the dual mechanism being the toxicological distinction.

Discusses how MAO inhibition by ring-substituted amphetamines (including methoxy-substituted compounds) influences pharmacology and toxicity.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedThe catechol metabolite di-OH-MA — implicated in MDMA neurotoxicity — is produced from PMMA at 2–7× lower levels, suggesting different neurotoxicity pathways.[8]model confidence 80%
Verified

Abstract confirms 'catechol metabolite di-OH-MA not major determinant of fatal toxicity,' supporting the conclusion that di-OH-MA plays a lesser role in PMMA neurotoxicity. The 2–7× quantification is not in the abstract but the conclusion is confirmed.

Catechol metabolite di-OH-MA not major determinant of fatal toxicity.

checked by claude-sonnet-4-6 · Apr 25, 2026

inconclusivePMA shares the dual release + MAO-A inhibition mechanism but is more potent at MAO-A (IC₅₀ ~300–600 nM vs ~1,700 nM for PMMA)[2]model confidence 70%
Inconclusive

Abstract covers MAO inhibitory properties of methoxy-substituted amphetamines (including PMA and PMMA per SCOPE), but the specific IC₅₀ values (300–600 nM vs 1,700 nM) are not present in the abstract text.

Review of structural modifications of amphetamine scaffold that modulate MAO inhibitory properties.

checked by claude-sonnet-4-6 · Apr 25, 2026

inconclusivePMMA and PMA are metabolically interconvertible: PMMA undergoes N-demethylation to PMA, and PMA undergoes O-demethylation to shared downstream metabolites.[8]model confidence 65%
Inconclusive

Abstract confirms PMA as a minor metabolite of PMMA (one direction), but does not describe PMA undergoing O-demethylation to shared downstream metabolites (the reverse direction is not addressed).

PMMA metabolized mainly to 4-hydroxymethamphetamine (OH-MA) in HLMs; PMA as minor metabolite.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedSimilar to but non-identical with MDMA — PMMA and MDMA fail to fully cross-generalise[24]model confidence 99%
Verified

Abstract directly states: 'PMMA and MDMA stimuli are similar but non-identical' and 'PMMA stimulus failed to generalize completely to cocaine, 8-OH DPAT, or R(-)MMA.'

PMMA and MDMA stimuli are similar but non-identical. PMMA stimulus failed to generalize completely to cocaine, 8-OH DPAT, or R(-)MMA.

checked by claude-sonnet-4-6 · Apr 25, 2026

verifiedShared with MBDB, 3,4-DMA, and both MDMA enantiomers, placing PMMA in the "MDMA-like" (entactogen) stimulus class[21]model confidence 99%
Verified

Abstract directly confirms PMMA stimulus generalized to S(+)-MBDB, R(–)-MBDB, S(+)-3,4-DMA, R(–)-3,4-DMA, and that PMMA, MBDB, 3,4-DMA, and MDMA share common stimulus effects.

PMMA stimulus (ED50=0.4 mg/kg) generalized to S(+)-MBDB, R(-)-MBDB, S(+)-3,4-DMA, R(-)-3,4-DMA. Evidence that PMMA, MBDB, 3,4-DMA, and MDMA share common stimulus effects distinct from DOM and amphetamine.

checked by claude-sonnet-4-6 · Apr 25, 2026

05

Coverage & Gaps

effect links
52 links · 52 approved · 22 audited0/52 with evidence basis
06

Research Trail

substance-article pipeline-v5 Apr 25, 2026

StepSourceQueryResults
1database lookupPubChempara-methoxymethamphetamine1 result, 1 selected
2literature searchPubMedPMMA para-methoxymethamphetamine pharmacology toxicology3 results, 3 selected
3literature searchOpenAlexPMMA para-methoxymethamphetamine deaths toxicity10 results, 3 selected
4document retrievalPubMedPMID 222579681 result, 1 selected
5document retrievalPubMedPMID 258443751 result, 1 selected
6literature searchPubMedpara-methoxymethamphetamine15 results, 5 selected
7literature searchOpenAlexPMMA para-methoxymethamphetamine pharmacology monoamine transporter10 results, 0 selected
8clinical trial searchClinicalTrials.govpara-methoxymethamphetamine PMMA0 results, 0 selected
9web searchWebSearchPMMA para-methoxymethamphetamine legal scheduling DEA Schedule I history10 results, 1 selected
10web searchWebSearchPMMA synthesis history first reported discovery10 results, 1 selected
11document retrievalHandWiki—1 result, 1 selected
12literature searchPubMedGlennon methoxymethamphetamine preliminary behavioral investigation 19881 result, 1 selected
13literature searchOpenAlexPMA para-methoxyamphetamine monoamine oxidase inhibitor serotonin releasing fatal10 results, 3 selected
14document retrievalPubMedPMID 10515329, 11420094, 17307247, 280655564 results, 4 selected
15document retrievalPubMedPMID 19261515, 19428944, 12726841, 129355734 results, 4 selected
16web searchWebSearchPMMA Argentina Time Warp deaths 201610 results, 0 selected
17document retrievalEUDA—1 result, 1 selected
18document retrievalErowid/PiHKAL—1 result, 1 selected
19web searchWebSearchPMMA Marquis Mecke Mandelin reagent test results color10 results, 1 selected
20legal status searchWebSearchPMMA UK Class A Germany Anlage I Canada Schedule I legal history10 results, 0 selected
Research document (raw, unedited pipeline output)
# Research Output: PMMA (para-Methoxymethamphetamine)

**PSX ID:** PSX-0303  
**Research date:** 2026-04-25  
**Substance readiness:** Emerging/sparse (< 0.3) — target ≥10 citations; achieved 30

---

## Chemical Identity

**Confirmed via PubChem CID 90766 [Ref 12 / PubChem direct lookup]:**

| Property | Value |
|---|---|
| IUPAC Name | 1-(4-methoxyphenyl)-N-methylpropan-2-amine |
| Molecular Formula | C₁₁H₁₇NO |
| Molecular Weight | 179.26 g/mol |
| InChIKey | UGFMBZYKVQSQFX-UHFFFAOYSA-N |
| PubChem CID | 90766 |
| CAS Number | 22331-70-0 [Ref 12] |
| SMILES | CC(CC1=CC=C(C=C1)OC)NC |
| ChemSpider ID | 81951 |

**Discrepancies with seed data:** The brief did not contain SMILES, molecular formula, molecular weight, or InChIKey. All have now been confirmed via PubChem and cross-referenced against HandWiki. No contradictions found.

PMMA is the N-methyl derivative of para-methoxyamphetamine (PMA); it is also the 4-methoxy analogue of methamphetamine. It exists as a racemate in clandestine tablets; the S(+) enantiomer is the pharmacologically active isomer (see Stereochemistry section below).

---

## Pharmacology

### Mechanism of Action

PMMA is a serotonin-preferring releasing agent and monoamine oxidase A (MAO-A) inhibitor. These two properties in combination are considered responsible for its disproportionate lethality relative to MDMA (Liechti 2015 [Ref 25]; Reyes-Parada et al. 2019 [Ref 24]).

**Monoamine transporter interactions:**
- Acts as a **substrate-type releaser** at the serotonin transporter (SERT) and norepinephrine transporter (NET), with comparatively weaker activity at the dopamine transporter (DAT) (Simmler et al. 2014 [Ref 8]; Liechti 2015 [Ref 25])
- The release profile is more serotonin-preferring than dopamine-preferring, distinguishing it from classic amphetamines but aligning it with entactogens such as MDMA
- Gołembiowska et al. (2015) [Ref 7] demonstrated via rat microdialysis that PMMA (5 and 10 mg/kg i.p.) enhanced extracellular release of both dopamine (DA) and 5-HT in the **striatum**, **nucleus accumbens**, and **frontal cortex**, similar to MDMA. Notably, PMMA increased 5-HT tissue content in the striatum, while cortical DA levels were *decreased* following PMMA

**MAO-A inhibition:**
- PMMA inhibits MAO-A, the enzyme responsible for catabolizing serotonin, norepinephrine, and dopamine in the synapse (Reyes-Parada et al. 2019 [Ref 24])
- Published IC₅₀ for PMMA at MAO-A: approximately **1,700 nM** — less potent than PMA (~300–600 nM) but clinically significant at recreational doses [Ref 24 — web-summarized; original data cited in Reyes-Parada review]
- MAO-A inhibition prevents the normal catabolism of serotonin released by PMMA's transporter activity, creating an additive serotonergic burden that underlies its capacity to cause serotonin syndrome and lethal hyperthermia (Liechti 2015 [Ref 25]; Gołembiowska et al. 2015 [Ref 7])
- No evidence of significant MAO-B inhibition has been reported

**⚠️ FLAG for human review:** The MAO-A IC₅₀ value of ~1,700 nM is derived from a web-summarized secondary source citing the Reyes-Parada review [Ref 24]. The primary IC₅₀ data from that review (which itself cites earlier experimental literature) should be verified by a researcher with full-text access before this value is presented as definitive in article prose.

**Receptor binding:**
- Published binding affinity data at specific receptor subtypes (5-HT₂A, D₁/D₂, adrenergic, etc.) is largely absent for PMMA specifically. Available data suggests receptor binding affinities at serotonergic and adrenergic sites are low, with transporter-mediated mechanisms predominating over direct receptor agonism (web sources; not confirmed by peer-reviewed primary research for PMMA)
- PMMA does not bind to trace amine-associated receptor 1 (TAAR1) in rodent preparations (inferred from its β-keto absence; Simmler et al. 2014 [Ref 8] confirmed non-β-keto amphetamines do bind TAAR1, implying PMMA may bind TAAR1 — this requires primary-source verification)

**Organic cation transporter:**
- PMMA is a substrate of **OCT2** (organic cation transporter 2) with Km in the 7.9–46 µM range; OCT2 mediates renal tubular uptake and excretion of PMMA (Jensen et al. 2020 [Ref 10]). The naturally occurring variant A270S shows modestly reduced transport capacity, potentially contributing to individual variability in PMMA elimination and toxicity

### Pharmacokinetics (Rat Data)

All pharmacokinetic data is from rat studies; no controlled human PK data has been published.

Rohanova & Balíková (2009) [Ref 18] administered PMMA 40 mg/kg subcutaneously to rats:

| PK Parameter | Value |
|---|---|
| Plasma Cmax | 4,014 ± 1,122 ng/mL |
| Tmax (plasma) | ~30 minutes |
| Half-life | ~1.0 hour |
| Volume of distribution | 6.4 L/kg |
| Plasma clearance | 4.4 L/h |
| Highest tissue concentration | Lungs (Cmax 42,988 ± 10,223 ng/g) |
| Brain/plasma ratio (PMMA) | 15.8 at 8 hours |
| Brain/plasma ratio (metabolite PMA) | 11.8 at 8 hours |

Páleníček et al. (2011) [Ref 5] (rats, oral-equivalent dosing) found serum peaks at ~30 min, but brain concentrations at the higher dose (20 mg/kg) peaked at ~1 hour — delayed relative to the 5 mg/kg dose, suggesting dose-dependent brain penetration kinetics. This delayed brain peak may underlie the danger of redosing: plasma effects appear to wane before full CNS action has occurred.

### Stereochemistry

Young et al. (1999) [Ref 14] established via drug discrimination in rats that **S(+)-PMMA** (ED₅₀ = 0.32 mg/kg) is the pharmacologically active enantiomer, essentially equipotent with the racemate (ED₅₀ = 0.41 mg/kg). **R(−)-PMMA** failed to produce complete stimulus generalization. Clandestine tablets contain racemic PMMA.

### Metabolism

**Human metabolism (liver microsomes + fatal cases):**
Vevelstad et al. (2017) [Ref 4] characterised PMMA human metabolism using genotyped human liver microsomes (HLMs) and blood samples from three fatal intoxications:

- **Major metabolite:** 4-hydroxymethamphetamine (OH-MA) — formed via aromatic hydroxylation
- **Minor metabolites:** para-methoxyamphetamine (PMA) via N-demethylation; 4-hydroxyamphetamine (OH-A); dihydroxymethamphetamine (di-OH-MA); oxilofrine (= OH-MA isomer)
- **CYP2D6 is the primary enzyme** responsible for PMMA metabolism; ultrarapid metabolizers form significantly more metabolites than poor metabolizers
- The catechol metabolite di-OH-MA was previously hypothesised to mediate PMMA neurotoxicity (as it does with MDMA); Vevelstad et al. found di-OH-MA formation from PMMA was **2–7× lower** than from an equimolar dose of MDMA, arguing against catechol metabolites as the primary determinant of PMMA lethality

**In vitro human metabolism (subcellular fractions):**
Lai et al. (2015) [Ref 11] confirmed that O-dealkylation (demethylation of the methoxy group) is the major pathway, followed by N-dealkylation, hydroxylation, and deamination. Phase II metabolism is limited. PMMA has a **slow metabolic rate** in vitro, potentially contributing to accumulation.

**Rat urine metabolism:**
Staack et al. (2003) [Ref 19] identified pholedrine (p-hydroxy-N-methylphenethylamine) as the major rat urine metabolite from O-demethylation; also PMA, 1-hydroxypholedrine diastereomers (including oxilofrine), and methoxy-hydroxy metabolites.

**⚠️ FLAG:** Oxilofrine and pholedrine are clinically used medications. Forensic differentiation of PMMA, PMA, and pholedrine intake requires consideration of this metabolic overlap (Staack et al. 2003 [Ref 19]).

---

## History

### Discovery and First Documentation

PMMA was documented by Alexander Shulgin in **PiHKAL (1991)** [Ref 27] under entry #130 as "METHYL-MA" — the N-methylated analogue of 4-MA (PMA). Shulgin reported testing PMMA at **110 mg orally**, observing tachycardia (pulse >100 bpm), compulsive yawning, and eye muscle disturbance resembling the physical side effects of MDMA without any central psychoactive effects. He returned to baseline by the fourth hour. Shulgin explicitly discouraged further human experimentation based on animal data showing catatonia and "unsuspected neurochemical changes" [Ref 27].

The first published peer-reviewed animal study of PMMA was Glennon et al. (1988) [Ref 1], which characterised PMMA's stimulus properties, locomotor effects, and acute toxicity in mice. This study found that racemic PMMA produced neither amphetamine-like nor DOM-like stimulus effects at doses up to 30 mg/kg.

Synthesis routes have been documented in forensic chemistry literature: PMMA can be produced via the **Leuckart reaction** from 4-methoxyphenyl-2-propanone (PMP2P), which is itself obtainable from trans-anethole (extracted from star anise) or from 4-methoxytoluene — both unrestricted chemicals in many jurisdictions as of 2017 (Tam et al. 2017 [Ref 21]).

### Appearance on Illicit Markets

PMMA emerged on European illicit drug markets in the late 1990s and early 2000s, predominantly in tablet form sold as "ecstasy" or mixed with PMA and/or MDMA. The EU Council placed PMMA under Schedule I controls in **February 2002** following 29 seizure incidents (18,870 tablets) across 15 EU member states and at least 3 associated deaths (EUDA 2002 [Ref 22]).

### Major Fatality Incidents

| Year | Location | Deaths | Notes |
|---|---|---|---|
| ~2002 | EU (various) | ≥3 | PMMA+PMA combination; EU scheduling trigger |
| 2003 | Germany | 1 | 22-year-old male; femoral blood PMMA 0.85 mg/L + PMA 0.61 mg/L (Becker et al. 2003 [Ref 20]) |
| 2010–2011 | Norway | 12 | 6-month "PMMA epidemic"; 22 non-fatal cases; drug known as "Death" (Vevelstad et al. 2012 [Ref 2]) |
| 2011 | Netherlands | 4 | Limburg province |
| 2011 | Scotland | 4 | Ecstasy-related deaths attributed to PMMA/PMA |
| 2011 | Canada (AB/BC) | 21 | ~45 total exposures; Calgary and Vancouver epicentres (Nicol et al. 2015 [Ref 3]) |
| 2012–2015 | Ireland | Multiple | Multiple reported deaths |
| 2016 | Argentina | 5 | "Time Warp" rave in Buenos Aires; 4 Argentine, 1 Uruguayan deaths; PMMA confirmed in victims |

**Note on Scotland and Ireland deaths:** Primary peer-reviewed publications specifically documenting these incidents were not located in the search. Numbers are derived from web-retrieved sources [Ref 12] and should be flagged for verification with primary forensic literature.

---

## Subjective Effects

### Human Data (Shulgin, PiHKAL #130)

At **110 mg orally** (the only documented controlled human experiment located in the literature):
- Tachycardia (pulse >100 bpm)
- Compulsive yawning
- Eye muscle disturbance (nystagmus-like)
- Physical side effects resembling MDMA without the central psychoactive effects
- Return to baseline by approximately **4 hours** [Ref 27]

Shulgin reported no euphoria, empathy, or psychedelic effects. At 100 mg, he noted increased blood pressure and heart rate without psychoactivity [Ref 27].

### Animal Drug Discrimination Data

Multiple drug discrimination studies (Glennon lab) characterised the PMMA stimulus as:
- **Not amphetamine-like**, **not DOM-like** (Glennon et al. 1988 [Ref 1])
- **Similar to MDMA** but non-identical: PMMA failed to fully generalise to cocaine, 8-OH-DPAT, and R(−)-MMA (Glennon et al. 2007 [Ref 16])
- Sharing stimulus properties with MBDB, 3,4-DMA, and both MDMA isomers — an "MDMA-like" (entactogen) stimulus class (Rangisetty et al. 2001 [Ref 15])
- PMMA is described as "less stimulant-like than MDMA" (Glennon et al. 2007 [Ref 16])

### Rat Behavioural Data

Páleníček et al. (2011) [Ref 5]:
- PMMA (5 mg/kg) increased overall locomotion
- PMMA (20 mg/kg) produced a **biphasic locomotor effect**
- PPI (prepulse inhibition) was decreased dose-dependently — indicating disrupted sensorimotor gating
- **Hyperthermic response only at 20 mg/kg** and only under **crowded conditions** (not isolated housing), paralleling the rave/dance environment risk

### Effects Taxonomy (Seed Data)

The following effects listed in the brief seed data are supported by the evidence base:
- **Stimulation, wakefulness, tachycardia, vasoconstriction, hyperthermia** — supported by Páleníček 2011 [Ref 5], Gołembiowska 2015 [Ref 7]
- **Excessive sweating** — noted by Shulgin at 110 mg; consistent with serotonergic hyperthermia
- **Nausea, dizziness, appetite suppression, bruxism, pupil dilation** — consistent with serotonergic/sympathomimetic class; no PMMA-specific primary data confirmed
- **Empathy enhancement** — not observed in Shulgin's account at documented doses; described as similar to but weaker than MDMA by animal studies; human entactogen effects not confirmed in peer-reviewed human trials
- **Cognitive euphoria, anxiety, visual effects (tracers, drifting, haze)** — not documented in any primary PMMA-specific source; may represent class inference from MDMA. **⚠️ FLAG: visual effects and cognitive euphoria are not supported by human primary data for PMMA; Shulgin explicitly noted absence of psychoactive effects at 110 mg**
- **Seizure threshold reduction** — supported by case reports (convulsions documented in fatal cases, Vevelstad 2012 [Ref 2])

**Duration estimate:** Based on Shulgin's account (return to baseline by ~4 hours at 110 mg) [Ref 27] and Páleníček rat data showing peak brain concentrations at ~1 hour [Ref 5], total duration appears to be 3–5 hours at recreational doses. No controlled human duration data exists.

---

## Safety & Toxicity

### Lethal Blood Concentrations

Vevelstad et al. (2012) [Ref 2] reported in the Norwegian epidemic:
- **Reported lethal range:** 0.6–3.1 mg/L in peripheral blood; 1.2–15.8 mg/L in heart blood
- **Median fatal concentration (peripheral):** 1.92 mg/L (range 0.17–3.30)
- **Median non-fatal concentration:** 0.07 mg/L (range 0.01–0.65)

### LD₅₀ (Mouse, Racemic PMMA)

Glennon et al. (1988) [Ref 1]:
- **Isolated LD₅₀:** 63 mg/kg
- **Aggregated LD₅₀:** 53 mg/kg
- No significant difference between isolated and aggregated conditions (unlike amphetamine, which shows pronounced aggregation toxicity)

Grokipedia (web source) cites an LD₅₀ of 80–100 mg/kg in **rats** with a therapeutic index 2–4× above behavioural doses. This rat LD₅₀ cannot be confirmed via peer-reviewed source and should be **⚠️ flagged for editorial verification**.

### Clinical Presentations in Fatal Cases

Death from PMMA is characterised by (Vevelstad et al. 2012 [Ref 2]; Nicol et al. 2015 [Ref 3]):
- Acute respiratory distress
- **Hyperthermia** (the dominant lethal mechanism)
- Cardiac arrest
- Convulsions / seizures
- Sudden collapse
- **Multiorgan failure** (in survivors: renal failure documented)
- **Serotonin syndrome** features: agitation, hyperthermia, muscle rigidity, autonomic instability

In Canada (Nicol et al. 2015 [Ref 3]), PMMA exposure was specifically characterised by "multiorgan dysfunction and serotonin syndrome, followed by cardiovascular collapse." Multiple synthetic amphetamines were co-present in toxicological analysis in most cases.

### Neurotoxicity Mechanisms

Shin et al. (2016) [Ref 6] demonstrated in mice that PMMA causes:
- Phosphorylation of **PKCδ** (protein kinase C delta) with mitochondrial translocation
- Oxidative stress predominantly in mitochondria (> cytosol)
- Reductions in mitochondrial membrane potential and Complex I activity
- Decrease in mitochondrial Mn-SOD
- Increase in intramitochondrial Ca²⁺
- Microglial activation (Iba-1-positive) and TNF-α upregulation
- **Dopaminergic striatal neuron loss**

PKCδ knockout and TNF-α knockout mice were both protected from PMMA-induced apoptosis and dopaminergic loss, establishing a PKCδ–TNF-α axis as a key mediator of PMMA neurotoxicity [Ref 6].

### Why PMMA is More Dangerous Than MDMA

The combination of:
1. **MAO-A inhibition** (prevents serotonin catabolism)
2. **SERT-mediated serotonin release** (increases synaptic serotonin)
3. **Delayed brain penetration** relative to plasma peak (users may redose before full CNS effect)
4. **Slow onset** vs MDMA (users take additional doses thinking the pill was inactive)
5. **Mitochondrial oxidative stress** mechanism of neurotoxicity

...creates a lethal combination not present with MDMA (Vevelstad et al. 2017 [Ref 4]; Liechti 2015 [Ref 25]).

### Polydrug Synergy

Poly-drug use was frequent in both fatal and non-fatal Norwegian cases (Vevelstad 2012 [Ref 2]). Three of 12 fatalities were PMMA-only; six involved PMMA + other psychostimulants; three involved PMMA + CNS depressants. PMMA+CNS depressants group had notably lower median PMMA concentrations (0.52 mg/L vs 3.05 mg/L for PMMA-only deaths), suggesting synergistic lethality at lower PMMA levels.

---

## Harm Reduction

### Delayed Onset Risk

The most critical harm reduction point for PMMA is its **delayed and slow onset** relative to MDMA. Users who believe they have taken an MDMA tablet may redose after 30–60 minutes, resulting in rapid dose escalation into lethal territory (EUDA 2002 [Ref 22]; Páleníček et al. 2011 [Ref 5]).

**Onset of plasma peak:** ~30 minutes (rat data [Ref 18])  
**Brain peak (higher doses):** ~60 minutes [Ref 5]  
**Subjective effects onset in humans:** likely 45–90 minutes (inferred)

### Reagent Testing

PMMA can be partially identified via colorimetric reagent tests [Ref 28]:

| Reagent | PMMA Result |
|---|---|
| Marquis | No colour change |
| Simon's | **Blue** (distinguishes PMMA as secondary amine from PMA which gives no blue) |
| Mecke | Green |
| Mandelin | Brown |
| Liebermann | Dark brown/black |
| Froehde | Light blue |

**Critical note:** A negative Marquis test does NOT exclude the presence of PMMA in an ecstasy tablet. PMMA-positive tablets have been misidentified as inactive by users testing with Marquis alone.

### Hydration

ADF Australia [Ref 23] recommends 250–500 mL water/hour while active (dancing) to mitigate dehydration; note that over-hydration is also dangerous. Regular breaks and temperature regulation are essential.

### Contraindications

- **MAOIs:** Double MAO inhibition risk — serotonin syndrome almost certain
- **SSRIs/SNRIs:** Combination with PMMA's serotonin-releasing and MAO-A inhibiting effects creates extreme serotonin syndrome risk
- **MDMA:** Additive serotonergic toxicity; combined use documented in multiple fatal cases
- **Stimulants (cocaine, amphetamine, methamphetamine):** Additive cardiovascular and hyperthermia risk (Nicol et al. 2015 [Ref 3])
- **CNS depressants (alcohol, opioids, benzodiazepines):** May mask early warning signs of hyperthermia; documented in Norwegian fatal cases with lower PMMA levels [Ref 2]
- **Pre-existing cardiac conditions, hypertension, hyperthyroidism** [Ref 23; Ref 29]

### Emergency Signs (Seek Immediate Medical Attention)

Per ADF Australia [Ref 23]: extremely high body temperature, seizures, difficulty breathing, loss of consciousness, kidney failure signs. Emergency treatment of PMMA toxicity is **supportive**: aggressive cooling for hyperthermia, benzodiazepines for seizures/agitation; cyproheptadine may be used for serotonin syndrome features.

---

## Tolerance & Dependence

**No published data exists** on PMMA-specific tolerance development, cross-tolerance, or dependence liability in humans.

Gołembiowska et al. (2015) [Ref 7] noted that PMMA's ability to increase DA and 5-HT tissue levels in rat brain regions suggests potential for dependence liability ("observed changes in brain monoamines suggest these drugs may be capable of development of dependence"), but this is a speculative inference from acute neurochemical data. No animal models of PMMA self-administration or conditioned place preference have been published in the searched literature.

**⚠️ FLAG:** Tolerance and dependence sections cannot be populated from primary data for PMMA. Any database values in these fields require editorial notation that they are class-inferred from MDMA/amphetamine literature, not PMMA-specific.

---

## Interactions

### Serotonin Syndrome

PMMA's dual mechanism (serotonin releasing + MAO-A inhibition) means that combination with ANY serotonergic drug carries severe serotonin syndrome risk. Documented dangerous combinations include:
- PMMA + MDMA (multiple fatal cases, Norway and Canada)
- PMMA + PMA (German fatal case [Ref 20]; EU deaths [Ref 22])
- PMMA + amphetamine (documented in Norwegian and Canadian cases)
- PMMA + SSRIs/SNRIs: class-inferred severe risk; no PMMA-specific case reports located
- PMMA + MAOIs: severe/potentially fatal; class-inferred

### CYP2D6 Drug Interactions

PMMA is primarily metabolised by CYP2D6 (Vevelstad et al. 2017 [Ref 4]). CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion, haloperidol, ritonavir) could markedly reduce PMMA clearance, raising blood concentrations and increasing toxicity risk. CYP2D6 poor metabolizers are at elevated risk from standard doses.

### Polydrug Combinations in Fatal Cases

Nicol et al. (2015) [Ref 3]: "when evaluating patients suspected of exposure to sympathomimetic drugs of abuse, clinicians must anticipate multiple clinical effects from the increased release of dopamine, serotonin, norepinephrine and other neurotransmitters" — specifically from multi-substance ecstasy tablets.

---

## Legal Status

| Jurisdiction | Status | Notes |
|---|---|---|
| United States | Schedule I | Effective July 26, 2021 (DEA final rule published June 25, 2021 [Ref 13]). Proposed rulemaking May 15, 2020 |
| United Kingdom | Class A | Covered as a methamphetamine derivative under the Misuse of Drugs Act 1971 |
| Canada | Schedule I | Listed in Controlled Drugs and Substances Act |
| Germany | Anlage I | Controlled under BtMG; permitted for authorised scientific use only [Ref 12] |
| Brazil | F2 list | Controlled [Ref 12] |
| European Union | Controlled | EU Council Decision February 28, 2002; all member states required to implement controls [Ref 22] |
| United Nations | Schedule I | 1971 Convention on Psychotropic Substances; added at 59th CND session, March 2016 [Ref 13] |
| Australia | Schedule 9 (inferred) | ADF classifies as prohibited; specific Poisons Standard entry not confirmed by reviewed source — **⚠️ FLAG** |

---

## Clinical Trials

No clinical trials for PMMA were found on ClinicalTrials.gov. No clinical therapeutic applications have been proposed for PMMA. This is consistent with its characterisation as a dangerous adulterant/substitute with no accepted medical utility.

---

## Dose / Duration Proposal

*Per Brief Part B directives, dose/duration proposals use evidence hierarchy: existing DB values → community consensus → structural analog inference.*

**Dose data (existing DB):** Common 100–120 mg oral — aligns with Shulgin's documented trial at 110 mg [Ref 27] and PiHKAL's listed minimum of 100 mg. This seed value is **confirmed by the evidence available**.

**Duration proposal (DB field empty):**
- Shulgin: returned to baseline by ~4 hours at 110 mg [Ref 27]
- Rat data: brain Cmax at ~60 minutes; serum Cmax at ~30 minutes [Ref 5, 18]
- Half-life in rats: ~1.0 hour [Ref 18]
- **Proposed total duration: 3–5 hours** (onset 60–90 min; peak 90–180 min; offset 3–5 hr total)
- This is considerably shorter than MDMA (3–5 hours) with a similar onset delay but faster offset
- **Editorial review required** — no controlled human duration study exists

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief.

---

## Gaps & Flags

### Safety-Critical Values Requiring Verification

1. **⚠️ MAO-A IC₅₀ ~1,700 nM for PMMA** — cited via web source summarising Reyes-Parada review [Ref 24]. Full-text access needed to confirm the primary experimental source of this value.

2. **⚠️ Rat LD₅₀ 80–100 mg/kg** — appears in web-retrieved source (Grokipedia); not confirmed in any located peer-reviewed paper. Mouse LD₅₀ data from Glennon 1988 (63 mg/kg isolated; 53 mg/kg aggregated) is the only peer-reviewed LD₅₀ data [Ref 1].

3. **⚠️ Australia Schedule 9 status** — not confirmed from an official or peer-reviewed source. ADF [Ref 23] treats PMMA as prohibited but does not specify schedule number.

4. **⚠️ Scotland (4 deaths, 2011) and Ireland (multiple deaths, 2012–2015)** — cited from web sources only; primary forensic publications documenting these specifically were not located.

5. **⚠️ Duration data** — no published human duration data; proposal based entirely on Shulgin's single-subject account (unverifiable book source) and rat pharmacokinetics.

6. **⚠️ Tolerance, cross-tolerance, dependence liability** — no primary data for PMMA. Any content in these fields must be flagged as class inference from MDMA/amphetamine literature.

### Contradictions with Seed Data

- **Psychoactive class: "Entactogen"** — The seed data lists PMMA as an entactogen. This classification is supported by animal drug discrimination evidence (generalises to MDMA stimulus class) but contradicted by Shulgin's human account at 110 mg, which found no empathogenic or entactogenic effects. The distinction may be dose-dependent: PMMA may produce entactogen-like effects at higher doses that are simultaneously in the dangerous/toxic range. **This contradiction should be addressed in article prose.**

- **Visual effects (tracers, drifting, haze)** — listed in seed effects taxonomy. No human primary data confirms visual effects for PMMA. Shulgin explicitly reported no psychoactive effects at 110 mg. This may be class-inferred from PMA or higher-dose speculation. **⚠️ FLAG: visual effects not confirmed by any PMMA-specific primary source.**

- **Cognitive euphoria** — similarly not confirmed by any PMMA-specific human data. Only animal discrimination data suggests MDMA-like stimulus character, which is not equivalent to reported human euphoria.

### Data Absent in Literature

- No controlled human pharmacokinetic studies (only rat data available)
- No binding affinity Ki data at specific monoamine receptors for PMMA
- No systematic review of PMMA-specific tolerance or dependence
- No published treatment protocol specific to PMMA toxicity (management follows general serotonin syndrome / sympathomimetic overdose protocols)
- No data on PMMA bioavailability in humans
- No data on PMMA dose-response for subjective/psychoactive effects in controlled human studies (single Shulgin account only)